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SUMMARY  
 
 
Lipoprotein X (LpX) is an abnormal cholesterol-containing particle that may be present 
in the serum of subjects with cholestasis, lecithin:cholesterol acyltransferase (LCAT) 
deficiency and parenteral nutrition. The biochemistry, metabolism, clinical significance 
and laboratory analysis of LpX is discussed in this study. This laboratory-based project 
investigated icteric samples received at the Chemical Pathology laboratory, Tygerberg 
Hospital, for serum predictors of LpX and the use of a modified non-denaturing 
polyacrylamide gradient gel electrophoresis system in the detection of LpX. The study 
showed that the non-denaturing polyacrylamide gradient gel electrophoresis system (2-
8%) is a useful test in demonstrating LpX in icteric plasma and has potential for a 
screening test in LCAT deficiency.  Serum concentration of conjugated bilirubin, alkaline 
phosphatase, gamma glutamyltransferase, free cholesterol, phospholipid, free cholesterol: 
total cholesterol ratio and conjugated bilirubin: total bilirubin ratio are all good predictors 
of LpX. The ratio of free cholesterol to total cholesterol (FC/TC > 0.6) was the best 
predictor of LpX. In the setting of obstructive liver disease LpX is seen in 66% of 
patients if total cholesterol is > 7.5 mmol/L. 
 
 
 
OPSOMMING 
 
 
Lipoproteien X (LpX) is ‘n abnormale cholesterol-bevattende partikel wat teenwoordig 
mag wees in die serum van persone met cholestase, lesitien:cholesterol asieltransferase 
(LCAT) gebrek en parenterale voeding. Die biochemie, metabolisme, kliniese belang en 
laboratorium analise van LpX word bespreek in hierdie werkstuk. Hierdie laboratorium-
gebaseerde projek het geelsugtige monsters ondersoek wat ontvang is by die Chemiese 
Patologie laboratorium, Tygerberg Hospitaal, vir serum voorspellers van LpX en die 
gebruik van ‘n gemodifiseerde nie-denaturerende polie-akrielamied gradiënt gel 
elektroforese sisteem in die demonstrasie van LpX. Die bevindinge was dat die nie-
denaturerende polie-akrielamied gradient gel elektroforese sisteem (2-8%) is ‘n nuttige 
toets om LpX te demonstreer in geelsugtige plasma en het potensiaal as ‘n siftingstoets in 
LCAT gebrek. Serum konsentrasie van gekonjugeerde bilirubien, alkaliese fosfatase, 
gamma glutamieltransferase, vry cholesterol, fosfolipied, vry cholesterol:totale 
cholesterol verhouding en gekonjugeerde bilirubien:totale bilirubien verhouding is alles 
goeie voorspellers van LpX. Die verhouding van vry cholesterol tot totale cholesterol 
(VC/TC > 0.6) was die beste voorspeller van LpX. In gevalle van obstruktiewe 
lewersiekte word LpX gesien in 66% van pasiente as die totale cholesterol meer as 7.5 
mmol/l is.   
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1. INTRODUCTION  
 
 
 
As a result of the high prevalence of atherosclerosis in the developed and developing 
world, and the clear link of hypercholesterolaemia with the atherosclerosis, blood is 
frequently analysed for hyperlipidaemia. It is also recognized that (cholestatic) liver 
disease is a cause of secondary dyslipidaemia. During investigation of liver disease it 
may be necessary to discriminate between primary and secondary dyslipidaemia. A more 
detailed analysis of lipoprotein fractions can aid in the aetiological diagnosis of 
dyslipidaemia.  
 
Lipoprotein X (LpX) is an abnormal cholesterol-containing particle that was first 
described in the 1950s. It may be present in the serum of subjects with obstructive 
jaundice, lecithin:cholesterol acyltransferase (LCAT) deficiency and parenteral nutrition.1 
The biochemistry, metabolism, clinical significance and laboratory analysis of LpX is 
reviewed in this study. This laboratory-based project investigated icteric samples 
received at the Chemical Pathology laboratory, Tygerberg Hospital, for serum predictors 
of LpX and the use of a non-denaturing polyacrylamide gradient gel electrophoresis 
system in the detection of LpX. 
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2. LITERATURE REVIEW  
 
 
 
In 1952, the occurrence of abnormal “lipoproteins” in the serum of patients with liver 
disease was detected on electrophoresis by Kunkel and Slater.1 In 1956, Russ et al 
identified this abnormal lipoprotein as low-density lipoprotein (LDL). It was lacking in 
cholesterol ester, and was called the “obstructive lipoprotein”. It has subsequently been 
named lipoprotein X (LpX). LpX was first believed to be specific for cholestasis, but 
later it was also identified in the serum of patients with familial LCAT deficiency, a 
disorder in which cholestasis is not a feature. 
 
 
2.1 Biochemistry and metabolism of LpX   
 
 
LpX is in fact not a true lipoprotein. The name lipovesicle X would be more appropriate. 
It consists of a lipid bilayer, enclosing an aqueous compartment, in a structure that 
measures 40 to 100 nm.2 Unlike lipoproteins it does not have a neutral lipid core. It 
appears as separate entities or rouleaux aggregates under electron microscopy. Although 
the density of LpX is in the LDL range, the physical size is in the range of very-low-
density lipoproteins (VLDL) or larger. LpX has a high content of phospholipid (± 65%) 
and unesterified (free) cholesterol (± 25%), as well as some apolipoproteinE (apoE), 
apoC and albumin.3 Albumin, other than trace quantities, is not present in any other 
known lipoprotein. LpX is devoid of apoB. It does not interact with the LDL receptor and 
cannot deliver cholesterol to the liver or down-regulate cholesterol synthesis.4  
 
Patsch et al described the subtypes LpX1, LpX2, and LpX3, with densities of 1.038, 1.049 
and 1.058, and Stokes radii of 339, 343, and 294 Ǻ, respectively.5 These investigators 
studied five patients with documented extrahepatic biliary disease and in each patient all 
three species of LpX was present. Bile acid content in LpX1, LpX2 and LpX3 was low, at 
0.04%, 0.04%, and 0.06% (w/w), respectively. The hepatotoxic lithocholic acid is the 
major bile acid in LpX.6 High-density lipoprotein (HDL) carries about 20% of total 
serum bile salts, and albumin carries the rest.7 In cholestasis there is a shift of bile salts 
from albumin to HDL. Studies with labelled taurocholate have demonstrated that LpX 
does not play a significant role in bile salt transport in cholestasis. 
 
The subtypes of LpX differ significantly in their content of apoAI and apoE. Each of the 
three subtypes contains albumin, but the antigenic determinant(s) of albumin are not 
accessible to the exterior of the particle. Paramagnetic resonance studies indicate that all 
three LpX fractions are extremely rigid.5 This rigidity is attributable to the high 
unesterified cholesterol and saturated fatty acid (myristic acid) content. The phospholipid 
fraction of LpX is predominantly lecithin.6    
 
The mechanism of formation of LpX is still poorly understood. It was initially believed to 
be an intestinal lipoprotein, normally catabolised by the liver, and accumulating as a 
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result of liver dysfunction.8 The possibility of bile salt inhibition of catabolic reactions 
has also been suggested, but the finding of similar bile salt concentrations in large duct 
obstruction, whether or not LpX was present, does not support this theory.8 Precursor 
lipoprotein complexes (containing phospholipids, unesterified cholesterol and albumin) 
are found in bile. In cholestasis, it is thought that these complexes are regurgitated into 
plasma.9 Experimentally, the addition of albumin or serum to bile results in the formation 
of particles indistinguishable from LpX. Class III p-glycoprotein (the canalicular 
translocator for phosphatidylcholine) on the hepatocyte canaliculi mediates the 
generation of LpX in biliary obstruction.2 Biliary vesicles are “re-transcytosed” to the 
sinusoidal surface to enter the circulation. Lipoprotein production rate is a modulator of 
the biogenesis of LpX. In LCAT deficiency, LpX probably forms secondary to the 
accumulation of phospholipids and unesterified cholesterol in serum.  
 
LpX is taken up and catabolised by the reticuloendothelial system, primarily by the 
spleen, unlike most other lipoproteins that are taken up by the liver.10 Receptor-binding 
studies indicate that isolated hepatocytes or fibroblasts exhibit a low degree of binding 
and uptake of LpX, whereas in lymphocytes high rates are observed. The exact mode of 
uptake is unknown. These cells show a marked reduction in the activity of the 
hydroxymethylglutaryl (HMG)-CoA-reductase when in contact with LpX. The reductase 
activity is greatly depressed in lymphocytes from cholestatic patients.  
 
 
2.2 Clinical Settings where LpX may be present in serum 
 
 
2.2.1 Cholestasis 
 
 
The liver plays a central role in lipoprotein synthesis and clearance (Table 1).11 Hepatic 
disease is accompanied by major qualitative and quantitative derangements of lipoprotein 
metabolism. The basic defects seen in liver disease are disturbed biosynthesis of 
lipoproteins, disturbed hepatic removal of lipoproteins from the circulation and disturbed 
plasma lipolytic activity.    
 
Cholestasis may be defined as a functional disorder of bile flow in which the 
characteristic chemicals (bile salts and bilirubin) spill over into the systemic circulation 
and induction of enzymes in the biliary canalicular lining may occur. Clinical and 
laboratory findings in patients with cholestasis include jaundice, dark urine, pale stools, 
pruritus, elevation of biliary tract enzymes in the plasma and conjugated 
hyperbilirubinaemia. Dyslipidaemic features include hypertriglyceridaemia with 
persisting apoB48, increased plasma phospholipids, decreased LCAT activity, and 
hypercholesterolaemia. The hypercholesterolaemia is mainly due to unesterified 
cholesterol, which is principally transported in the form of LpX. Hypercholanaemia is not 
regularly documented but is typical of cholestasis. 
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Table 1: Role of the liver in lipid metabolism (from ref 11) 
Lipoproteins Apolipoproteins Enzymes and receptors 
VLDL secretion 
Discoid HDL secretion 
IDL, LDL removal 
Chylomicron remnant 
removal 
IDL-LDL interconversion 
HDL2-HDL3 
interconversion 
Excretion of cholesterol 
returned to the liver by 
reverse cholesterol transport 
 
Synthesis of 
apolipoproteins AI, AII, 
B100, C, E 
LCAT 
Hepatic lipase 
Cholesterol ester transfer 
protein 
LDL receptor 
Chylomicron remnant 
receptor 
 
 
The precise cause of the hypercholesterolaemia of cholestasis is unknown, but several 
factors may contribute. Deficiencies of hepatic lipase, lipoprotein lipase and LCAT may 
occur in cholestasis.12 One study showed that LpX fails to inhibit HMG CoA reductase in 
cultured human hepatoma cells, and therefore may play a role in the pathogenesis of 
hypercholesterolaemia in the cholestatic patient by on-going biosynthesis of cholesterol 
even in the state where cholesterol may not be re-absorbed.4 However, LpX does not 
interfere with the ability of LDL to decrease reductase activity. In another study, LpX 
infused into rats did not reduce hepatic cholesterol synthesis.13 In fact, enhanced HMG 
CoA reductase activity (suggesting stimulation of cholesterol synthesis) and depressed 
cyp7 activity (suggesting less efficient conversion of cholesterol into bile acids) occurs in 
cholestatic liver disease.14 As LpX carries apoE, it may competitively inhibit 
chylomicron remnant uptake in hepatocytes, contributing to the dyslipidaemia of 
cholestasis. 
 
In α-naphthylisothiocyanate-treated mice, where cholestasis is induced by this 
hepatotoxin, phospholipids and free cholesterol (corresponding to the appearance of 
LpX) increase promptly, peaking at 48 hours.14 In experimental cholestasis, LpX may be 
detected and quantified as early as 24 hours after ligation of the common bile duct. In 
cases of proven large duct extrahepatic obstruction, LpX had disappeared within two 
weeks of surgery.8 
 
LpX is regarded as the most sensitive and specific biochemical parameter for the 
diagnosis of intra- and extrahepatic cholestasis.15 Detection of LpX is of high specificity 
(1) and predictive value (1), but lacks sensitivity (0,57) in intrahepatic cholestasis.15 In 
extrahepatic cholestasis however, the diagnostic sensitivity is 100%. Causes of 
intrahepatic cholestasis include primary biliary cirrhosis, alcoholic and viral hepatitis, 
and drug-induced cholestasis. Extrahepatic cholestasis results from obstruction of major 
bile ducts commonly due to gallstones and carcinoma of the pancreas or bile ducts. The 
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distinction between intrahepatic and extrahepatic cholestasis is of critical clinical 
importance, as it influences management. This distinction is best done by ultrasound 
imaging. Investigations into the utility of LpX have not been encouraging for 
discrimination of intrahepatic versus extrahepatic cholestasis. 
 
Magnani and Alaupovic utilised quantitative assays of LpX in the differentiation of 
extrahepatic and intrahepatic cholestasis.16 They claimed that LpX measurements may be 
more reliable than standard liver function tests in separating these disorders and stated 
that LpX-cholesterol values over 300 mg/dL (7.8mmol/L) are highly suggestive of 
extrahepatic obstruction. Ritland concluded that values over 400 mg/dL (10.4mmol/L) 
are highly indicative of extrahepatic biliary obstruction.17 Other investigators reported 
that the quantitative assay of LpX levels has little or no clinical value in differentiating 
extrahepatic from intrahepatic cholestasis.18 Wengeler et al claimed that the combined 
detection of LpX and determination of LCAT activity enables differentiation of 
extrahepatic from intrahepatic cholestasis.19 Degenaar et al suggested that the 
combination of LpX and the α2β fraction of gamma glutamyltransferase (GGT) permits 
this differentiation.20 Schut and Diaz concluded that the combined determination of high 
molecular mass alkaline phosphatase (ALP) and LpX offered the best results.21 Seidel et 
al analysed LpX in 1481 subjects, concluding that LpX has a specificity of 0.98 to 
demonstrate or exclude cholestasis.22 LpX was positive in all cases of extrahepatic biliary 
obstruction, even though some cases had normal ALP activities. Tazawa et al found that 
the combination of LpX and GGT level differentiated biliary atresia from intrahepatic 
cholestasis in infants.23  
 
The administration of cholestyramine helps in differentiating intrahepatic and 
extrahepatic cholestasis. Disappearance of LpX after a 2-week course of cholestyramine 
is consistent with intrahepatic cholestasis.24 However, cholestyramine is contraindicated 
in complete biliary obstruction and compliance is usually poor owing to the coarse 
texture of this powder. Witt and Ober found that LpX was present in the serum of about 
50% of infants during the first weeks of life and persisted for several months.25 In 
neonates, LpX levels do not correlate with bilirubin, cholesterol or GGT levels. LpX is 
more prevalent in premature neonates. The presence of LpX in newborns is thought to be 
due to immature liver function. Thus LpX can only be used as a marker of cholestasis 
after the first year of life.  
 
 
2.2.2 LCAT Deficiency 
 
 
The plasma enzyme lecithin: cholesterol acyl transferase (LCAT) uses lecithin and free 
cholesterol as substrates to produce lysolecithin and cholesterol esters. LCAT deficiency 
may be primary, due to a rare inborn error of metabolism or secondary to hepatocellular 
necrosis and cholestasis. Familial LCAT deficiency is a rare autosomal recessive genetic 
disorder which may be complete or partial (Fish Eye Disease).26 The lack of LCAT 
activity leads to an increase in the plasma concentrations of unesterified cholesterol and 
phosphatidylcholine, resulting in hypoalphalipoproteinemia and other lipoprotein 
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abnormalities. Clinical manifestations of complete LCAT deficiency include corneal 
opacities, corneal arcus, xanthomata, haemolytic anaemia and proteinuria. The majority 
of patients develop progressive glomerulosclerosis, which may lead to chronic renal 
failure. Heterozygotes display approximately 50% of normal plasma LCAT activity and 
none of the biochemical or clinical manifestations of the disorder.27  
 
Low HDL-cholesterol (HDL-C) concentration is an independent cardiovascular risk 
factor. The protective effect of HDL is thought to be mainly through reverse cholesterol 
transport. Despite reduced HDL, most patients with Familial LCAT deficiency or Fish 
Eye Disease do not appear to have increased risk for developing cardiovascular disease 
(CVD). However, in a subset of these patients premature CVD has been described.  
 
In a study of LCAT knockout mice, LpX was only present in a subset of mice, after being 
on a high fat, high cholesterol diet.28 LCAT deficiency reduces plasma levels of the 
atherogenic apoB containing lipoproteins by modulating the hepatic expression of the 
LDL receptor and apoE, which leads to reduced atherogenic risk. The study also showed 
that LCAT knockout mice had a dramatic increase in their plasma cholesterol ester levels 
on the atherogenic diet, suggesting enhanced contribution by the enzyme 
acylCoA:cholesterol acyltransferase (ACAT) responsible for the intracellular 
esterification of cholesterol.  
 
Paradoxically, a study of a Canadian family with LCAT deficiency showed that increased 
HDL-C in heterozygote LCAT deficient individuals may be associated with enhanced 
progression of atherosclerosis.26 This may be related to “dysfunctional” HDL. 
Heterozygotes for LCAT deficiency have a highly atherogenic lipoprotein profile, and it 
is possible that this defect may be underdiagnosed in the general population.  
 
 
2.2.3 Parenteral Nutrition 
 
 
During intravenous lipid emulsion infusions, liposome-rich emulsions, such as 10% or 
20% Intralipid® or Lipovenous®, induce plasma lipid accumulation, and the appearance 
of LpX-like particles.29 The ratio of medium-chain triglycerides to long-chain 
triglycerides in fat emulsions used in total parenteral nutrition influence the appearance of 
LpX.30 Cholestasis is also a possible complication of parenteral nutrition. 
 
 
2.3 Clinical consequences of LpX 
 
 
2.3.1 Renal Disease 
 
 
Renal failure represents the major cause of morbidity and mortality in subjects with 
LCAT deficiency. The presence of LpX has been noted to be closely associated with the 
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occurrence of renal failure in LCAT deficiency, and the level of LpX has been suggested 
as a biological marker of the evolution of renal disease in this condition.27 
 
The histological findings of the glomerulopathy seen in familial LCAT deficiency 
include glomerular lipid deposition. The direct deposition of LpX is the main cause for 
the accumulation of lipids in perfused rat kidney.31,32 Studies suggest that the 
accumulation of LpX may be responsible for progressive glomerulosclerosis by inducing 
a pro-inflammatory response and causing glomerular capillary endothelial damage.28,33,34 
Glomerular lipid deposition is also seen in patients with chronic cholestatic liver disease, 
for instance in Alagille syndrome.35  
 
 
2.3.2 Atherosclerosis 
 
 
LpX is thought not to be atherogenic, but cases of severe cardiovascular disease 
associated with LpX have been described. In contrast, certain findings suggest that LpX 
may protect against atherosclerosis. Patients with primary biliary cirrhosis (PBC) have a 
low incidence of atherosclerosis, in spite of significant hypercholesterolaemia.36 PBC is a 
chronic, progressive disease characterized by immune-mediated destruction of 
intrahepatic bile ducts, eventually terminating in cirrhosis and liver failure. High HDL-C 
and low lipoprotein(a) seen in PBC protect against atherosclerosis, but other factor(s) 
may also prevent atherosclerosis in these patients.36 In a recent study, LpX isolated from 
patients with PBC prevented LDL from becoming oxidised by CuSO4 and also prevented 
oxidised LDL from disrupting the fibroblast growth factor 2-dependent survival 
mechanism in vascular endothelial cells.37 It is thought that LpX is resistant to copper 
oxidation due to the high rigidity of the particle, thereby preventing penetration of copper 
ions into the hydrophobic region of the bilayer, where oxidizeable unsaturated fatty acids 
are localized. LpX also has a high affinity for copper ions. Although bilirubin is a potent 
antioxidant, there was a lack of detectable bilirubin in the LpX fractions isolated. It may 
also be that what is regarded as atherogenic hyperlipidaemia due to LDL-C actually 
represents LpX. One study in particular, which is often quoted to show that high LDL-C 
in PBC does not cause an elevated atherosclerosis risk used LDL-C calculated by the 
Friedewald equation, which does not apply because LpX is thereby incorrectly included 
in the LDL-C concentration.38  
 
Alagille syndrome (AGS) is an autosomal-dominant disorder characterised by paucity of 
interlobular bile ducts with cholestasis, and abnormalities of the heart, eye and vertebrae, 
as well as a characteristic facial appearance. Patients usually present with cholestasis 
within the first year of life, with episodes of jaundice interspersed by periods of 
remission. High cholesterol levels with hypoalphalipoproteinemia and LpX are detected 
during episodes of severe jaundice, while hyperalphalipoproteinaemia occurs during mild 
jaundice. A study of 22 children with AGS revealed that the distribution of excess 
cholesterol, and presence of LpX, depends on LCAT activity, and not on bilirubin level.39 
LCAT activity may be decreased due to decreased hepatic synthesis or the presence of an 
inhibitor during cholestasis. Decreased LCAT activity leads to an accumulation of 
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unesterified cholesterol, which may associate with phospholipids to form LpX. In 
contrast, another study of 5 children with AGS demonstrated LpX in 2 patients with 
normal LCAT activities.40  
 
HDL enrichment with apoE is seen in AGS. It has been hypothesised that apoE-enriched 
HDL facilitates reverse cholesterol transport by promoting cellular efflux and influx of 
sterols.40 HDL enriched with apoE may also help reverse cholesterol transport because of 
their recognition of the hepatic apoE receptor. The HDLs are also enriched with 
phospholipids, and the amount and composition of phospholipids present on HDL may 
determine their ability to remove cellular free cholesterol. ApoAI is important in reverse 
cholesterol transport. Since apoAI levels are sufficient in AGS and familial LCAT 
deficiency, the risk of atherosclerosis is not increased.39,40 The apoE-rich HDL seen in 
biliary obstruction might inhibit platelet aggregation, decrease thrombus formation and 
decrease the risk of coronary artery occlusion.             
 
A recent study compared carotid intimal-medial thickness (c-IMT) and wall stiffness (c-
WS) between children with AGS, progressive familial intrahepatic cholestasis (PFIC) and 
familial hypercholesterolaemia (FH).41 c-IMT and c-WS values of patients with AGS 
were normal, even though their TC and LDL-C levels were higher than the children with 
FH, whose c-IMT levels were significantly higher than those of age-matched normal 
control subjects. The elevated HDL-C seen in AGS may explain this, but the presence of 
LpX in these patients may have an additional inhibitory effect on the development of 
atherosclerosis. In this study LDL-C was measured by an enzyme immunoassay, which 
does not recognize LpX to a significant degree.  
 
 
2.3.3 Hyperviscosity syndrome 
 
 
The hyperviscosity syndrome is a dangerous consequence of high LpX concentrations in 
plasma. Prophylactic lipid apheresis should be considered if viscosity is > 3 
centipoise.42,43 Symptoms suggestive of hyperviscosity include visual changes, vertigo, 
ataxia, and changes in mental state. Clinical signs of hyperviscosity include dilated, 
segmented, and tortuous retinal veins, resulting in a “sausage-link” appearance.42 If not 
recognised, it could lead to seizures and coma, bleeding diathesis, and volume overload 
with congestive heart failure.43 
 
 
2.3.4 Pseudohyponatraemia 
 
 
Pseudohyponatraemia, defined as a spuriously low serum or plasma sodium 
measurement, occurs with dilutional methods of sodium analysis due to an altered 
fraction of total plasma volume occupied by high molecular weight substances or a lipid 
phase, most commonly with severe hypertriglyceridaemia or paraproteinaemia.44 Less 
commonly, pseudohyponatraemia is found in severe hypercholesterolaemia. Routine 
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measurement of serum sodium concentration by indirect ion-selective electrode involves 
dilution of the sample and is therefore prone to inaccuracy in severe 
hypercholesterolaemia due to LpX.  The discrepancy between the measured and 
physiological sodium concentration may lead to serious errors in patient management.  
 
 
 
2.3.5 Xanthoma 
 
 
In chronic cholestasis, for instance in PBC, LpX can cause extensive cutaneous 
xanthomata. The planar xanthomata found on the eyelids, referred to as xanthelasma, are 
regarded as a typical clinical association of PBC. Additionally, xanthomata of peripheral 
nerves can lead to a painful sensory neuropathy. Medical treatment to reduce LpX levels 
has been found to be unsatisfactory, and HMG CoA reductase inhibitors (statins) are 
contraindicated in the setting of liver disease.45 LDL-apheresis to remove LpX has been 
reported as successful in a patient with PBC who had planar xanthomata of both hands, 
interfering with his ability to work.46  
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3. LABORATORY ANALYSIS 
 
 
 
The discussion in this section will indicate that there is no simple, reliable method to 
isolate or measure LpX in a clinical chemistry laboratory. The isolation may introduce 
changes and the measurement may describe only a component of LpX. 
 
 
3.1 Isolation of LpX 
 
 
Seidel et al isolated LpX by ultracentrifugation (at 4ºC) of citrated plasma obtained from 
blood of patients with cholestasis.47,48 As plasma was layered under buffer solution with a 
density of 1.0055 g/ml, the VLDL fraction with a density less than 1.006 g/ml rose to the 
top. This was removed by a tube slicing technique. The fraction with density greater than 
1.006 g/ml was further fractionated by precipitation with heparin and manganese. After 
the precipitated lipoprotein was reprecipitated twice with magnesium chloride, heparin 
was removed by precipitation as heparin-barium mixture by dialysing the dissolved 
lipoprotein precipitate against barium chloride. The supernatant fluid resulting from low-
speed sedimentation of heparin-barium precipitate was fractionated with ethanol using 
Cohn’s procedure. This fractionation resulted in precipitation of Cohn Fractions I and III 
(which normally contain LDL). The supernatant solution made up of Cohn Fractions IV 
to VI was used to isolate LpX. This was accomplished by adjusting the density of the 
solution to 1.063 g/ml with sodium chloride and prolonged ultracentrifugation. LpX was 
in the fraction that had a flotation of 1.006 to 1.06 g/ml. By other isolation procedures, 
the fraction containing LpX was further subjected to zonal ultracentrifugation or 
hydroxyapatite chromatography. 
  
Generally-used isolation techniques entail precipitation of LpX with heparin and 
manganese chloride, and subsequent utilization of a combination of techniques, such as 
ethanol precipitation and sequential ultracentrifugation, zonal gradient ultracentrifugation 
with or without prior ethanol fractionation or hydroxyapatite chromatography.48 
 
 
3.2 Assay Methods 
 
 
In the 1960s, a system of agar gel electrophoresis was described by Seidel et al.47 With 
this method, LpX moves toward the cathode by electroendosmosis. Electroendosmosis 
may be defined as preferential movement of water in one direction through an 
electrophoresis medium due to selective binding of one type of charge on the suface of 
the medium.49 In agarose gel electrophoresis (AGE) less electroendosmosis takes place 
and LpX migrates very slowly towards the anode. Therefore it does not discriminate as 
effectively as agar gel electrophoresis.50 Chylomicrons migrate similarly and distinction 
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from LpX is sometimes problematic. A typical greenish discolouration helps with the 
identification of LpX. Figure 1 illustrates the possible patterns seen on AGE. 
 
Figure 1: AGE patterns 
 
 
 
 
Agar gel electrophoretic demonstration of LpX is enhanced by the application of 
polyanions on the surface of the gel on the cathodal side of the well or by 
immunodiffusion, applying antiserum against apoC.51 By densitometry of precipitation 
areas obtained after serum electrophoresis in agar gel followed by precipitation with 
polyanions, LpX can be quantified.52 
   
A method for quantitative estimation of LpX based on the assay of phospholipids in 
precipitates of LpX has been described. This correlated well with results of agarose gel 
electrophoresis.53 Other lipoproteins are first removed by precipitation with 
phosphotungstic acid solution. LpX is then precipitated from the supernatant fluid with 
an alkaline solution of magnesium ion, and phospholipid is determined in this precipitate. 
 
A commonly used selective immunoprecipitation method was described by Poittevin et 
al.38 Plasma is first treated with an anti-apoB serum. Alternatively, apoB-containing 
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lipoproteins can be precipitated by concanavalin A.40 Supernatant containing HDL and 
LpX is then treated with phosphotungstate acid, pH 6.15, to precipitate the LpX. The 
LpX is then redissolved in sodium citrate (0.2 mol/L) and phospholipids and total 
cholesterol are then determined by conventional assays.    
 
A turbidimetric method for determination of LpX is based on the separation of 
interfering lipoproteins by precipitation with heparin and zinc acetate followed by 
centrifugation.54 In the supernatant the LpX, which is not precipitated under these 
conditions, is determined by measuring the turbidity after the addition of calcium 
chloride and heparin. 
 
Another turbidimetric method involves the selective removal of apoB-containing 
lipoproteins by precipitation with specific antibodies.55 To the supernatant, sodium-
dodecyl sulphate (SDS) and MgCl2 are added to precipitate LpX, and the turbidity is then 
measured at 360 nm.   
 
Enzymatic determination of LpX has also been described.56 Non-esterified cholesterol is 
determined enzymatically with the cholesterol oxidase-peroxidase reaction using phenol 
and 4-aminophenazone as chromogens. This assay is done with the supernatant 
containing LpX, after other serum lipoproteins have been removed by precipitation with 
heparin and zinc acetate followed by centrifugation. Although LpX consists of the 
subfractions LpX1, LpX2 and LpX3, with slightly different cholesterol contents, this does 
not seriously affect the LpX determinations based on cholesterol content. 
 
A dye-binding method for rapid colorimetric determination of LpX involves the staining 
of serum lipoproteins by the addition of Sudan Black B solution.57 The normal 
lipoproteins and the excess of Sudan Black are removed with heparin and zinc acetate 
solution. LpX remains in the supernatant, and the blue colour is then measured. An 
empirically obtained constant is used for calculation. 
 
Two colorimetric procedures for quantitative determination of LpX, based on ether-
extractibility of phospholipids in LpX have been described.58 Phospholipids are relatively 
loosely bound in LpX. The major part of them can be extracted with ether. Since the 
extraction is not quantitative, especially at low LpX concentration, it was necessary to 
add a detergent to complete the extraction. The cationic detergent 
cetyltrimethylammonium bromide at the appropriate concentration was found to meet 
these requirements. 
 
Ritland described a method in which endogenous free cholesterol of the plasma 
lipoproteins is equilibrated with exogenous labelled cholesterol during an incubation at 
37ºC for four hours.59 After separation of LpX from the other lipoproteins by 
electrophoresis in agar, the percentage of the label found in the LpX fraction was 
measured by liquid scintillation. Based on this percentage, the plasma concentration of 
free cholesterol and the known composition of LpX, the concentration of LpX is 
calculated. 
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LpX has also been studied by 1H and 31P nuclear magnetic resonance.60 
 
LDL fractions can be separated by size exclusion column chromatography, where LpX 
will be detected as an additional peak.37 
   
A modified non-denaturing polyacrylamide gradient gel electrophoresis (GGE) system 
as described by Blom et al has proven useful in the diagnosis of 
dysbetalipoproteinaemia.61 GGE separates particles according to size and is also a useful 
method to identify LDL and HDL subspecies. Its potential utility in the detection of LpX 
was investigated in this project. The experience of the lipid laboratory in the Lipidology 
Division of the Internal Medicine Department at Groote Schuur Hospital and the 
University of Cape Town suggested a typical band could identify LpX. Figure 2 depicts 
the patterns of dyslipidaemia that can be recognised on a GGE that separates lipoproteins 
containing apoB. 
 
Figure 2: GGE patterns 
 
 
 
 
3.3 Analytical Considerations 
 
 
LpX is destroyed by freezing.57 It can be stored for 2 weeks at about 4ºC.57 
 
In cholestasis, high-molecular-mass ALP and ALP-LpX complex may complicate the 
interpretation of ALP isoenzyme electrophoresis.62 High-molecular-mass ALP isoenzyme 
represents fragments of hepatic cell plasma membranes with various membrane-bound 
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enzymes localized on the surface.63,64 Weijers and others demonstrated the existence of 
an ALP-LpX complex as an abnormally moving band (also called ultrafast liver 
isoenzyme) in the electrophoretic pattern of sera from patients with cholestasis.65,66 This 
complex was purified and studied by gel filtration and affinity chromatography.67 The 
position of the abnormally moving band in the alkaline phosphatase pattern and the 
percentage of alkaline phosphatase activity in the complex in relation to the total serum 
alkaline phosphatase activity depend on the serum LpX concentration. The presence of 
this complex is a reliable indicator of cholestasis, but is of limited value in the 
differentiation between intrahepatic and extrahepatic cholestasis. 
 
According to one study, elevated ALP is the best predictor of the presence of LpX in 
liver disease.68 In cholestasis, there is a mean increase in total cholesterol of 0.002 
mmol/L per unit increase in ALP.68  
 
Bile salts have been shown to act on LpX in vitro and cause a false-negative 
electrophoretic test. Frison et al have shown that bile salt levels more than five times the 
concentration that is usually seen in cholestasis are required for a change in 
electrophoretic pattern to occur.69 No relationship between serum LpX and serum bile 
acids, either positive or negative, was found in 29 patients with cholestasis and detectable 
LpX. 
 
LpX cannot be demonstrated by agar gel electrophoresis after incubation with lipoprotein 
lipase or postheparin plasma (which causes a release of lipoprotein lipase from 
endothelium).70 This change in electrophoretic mobility may be induced by the release of 
free fatty acids. These impart a negative charge to the particle, resulting in migration 
towards the anode. Activity of lipoprotein lipase in postheparin plasma is low in patients 
with cholestasis. This may explain why in some patients with cholestasis, LpX may still 
be found by electrophoresis also after incubation of postheparin plasma. 
 
LDL-cholesterol (LDL-C) is calculated in most routine clinical laboratories by the use of 
the Friedewald calculation. The formula is unreliable in non-fasting samples, if the 
triglyceride value exceeds 4,52 mmol/L, in dysbetalipoproteinaemia and in certain 
secondary dyslipidaemias. In such cases, direct measurement of LDL-C can be performed 
by ultracentrifugal single spin analysis, detergent assays or immunoprecipitation 
techniques. When the Friedewald formula is used, the estimated LDL-C concentration 
includes cholesterol contained in other lipoproteins, such as LpX. Direct methods for 
LDL-C determination recognise LpX to variable degrees.71  
    
Although no direct link with LpX could be established, a study has demonstrated that 
homogeneous HDL-C assays significantly underestimate HDL-C compared with single 
vertical-spin ultracentrifugation in liver cirrhosis.72 However, these investigators froze 
samples before analysis, and therefore no LpX would have been detected. This 
underestimation is probably due to LCAT deficiency, resulting in increased apoA-poor 
nascent HDL, which is not identified correctly by the homogeneous assays.  
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In immunonephelometric assays of lipoprotein(a), it has been shown that the presence of 
LpX may cause falsely elevated results.73  
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4. AIM(S) OF THIS PROJECT 
 
 
 
A cheap, sensitive and specific method for determining LpX as a secondary cause of 
hypercholesterolaemia in cholestasis would be useful and could also suggest LpX due to 
LCAT deficiency and parenteral nutrition. The lipid laboratory at Groote Schuur Hospital 
and University of Cape Town observed a large particle staining with a lipid stain in some 
patients with hypercholesterolaemia and cholestatic liver disease. This was attributed to 
LpX. It was thus of interest to do a systematic evaluation in patients with jaundice for this 
phenomenon.  
 
The aims of this study were to describe the prevalence of the putative LpX in icteric 
samples sent to the Chemical Pathology laboratory at Tygerberg Hospital in which LpX 
could be expected. Blood samples of patients with jaundice were run on lipoprotein 
B/LDL (LpB) polyacrylamide gradient gel electrophoresis (GGE) to detect LpX.  
 
Apart from the GGE, various parameters and ratios known to associate with LpX were 
evaluated: total bilirubin (TB), conjugated bilirubin (CB), alkaline phosphatase (ALP), 
gamma-glutamyl transferase (GGT), aspartate transaminase (AST), alanine transaminase 
(ALT), total cholesterol (TC), HDL-cholesterol (HDLC) (including subtypes HDL2C and 
HDL3C), triglyceride (TG), bile acid (BA), phospholipid (PL) and free cholesterol (FC) 
concentration. LpB GGE was compared with AGE in a subset of samples, as AGE was 
an affordable and available method for detection of LpX. As reported HDL may 
disappear or an abnormally large HDL subtype (HDL1) may be detected in cholestasis 
and thus the investigation was extended to include GGE for HDL or LpA particles.74,75 
The laboratory and clinical data in those patients with and without putative LpX were 
reviewed.  
 
 
 25
5. METHODS AND MATERIALS 
 
 
 
This is a descriptive and prospective study, approved by the Ethics Committee of the 
University of Stellenbosch. The project was funded through profits from contract 
research undertaken by Prof A D Marais. 
 
 
5.1 Samples 
 
 
The samples were collected between 28/02/2005 and 16/03/2006. Icteric samples 
received at the NHLS Chemical Pathology laboratory Tygerberg Hospital for analysis of 
a liver profile were stored in the 4ºC refrigerator and analyzed within a week by gradient 
gel electrophoresis in batches at the Lipidology Laboratory, University of Cape Town. 
Liver function tests were requested on these samples by physicians and the liver panel 
was performed in the NHLS Chemical Pathology laboratory, Tygerberg Hospital. In all 
patients a LpB GGE was performed and TB concentration measured. Depending on the 
volume of sample, in subgroups of the study population TC, HDL-C concentration 
(including subtypes HDL2C and HDL3C) and TG concentration, PL, BA concentration 
and FC concentration were measured, and AGE as well as LpA GGE was performed. The 
laboratory, demographic and clinical data in those patients with and without LpX was 
reviewed.  
 
 
5.2 Liver function tests 
 
 
5.2.1 Total bilirubin (TB) 
 
 
Bilirubin reacts with diazo sulfanilic acid at a low pH to produce azobilirubin. The 
presence of caffeine permits the rapid reaction of both conjugated and unconjugated 
bilirubin. The absorbance of the azobilirubin complex is measured as an endpoint 
reaction at 545 nm. The assay was performed on the Bayer Advia 1650 Chemistry 
analyzer. 
 
 
5.2.2 Conjugated bilirubin (CB) 
 
 
Bilirubin reacts with the diazo reagent (sulfanilic acid) at a low pH to produce 
azobilirubin. In the absence of caffeine only a rapid reaction with conjugated (“direct”) 
bilirubin occurs. The absorbance of the azobilirubin complex is measured as an endpoint 
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reaction at 545 nm. The assay was performed on the Bayer Advia 1650 Chemistry 
analyzer. 
 
 
5.2.3 Alkaline phosphatase (ALP) 
 
 
The sample is added to a p-nitrophenyl phosphate substrate. DEA buffer is used to 
maintain the reaction at pH 9,7 to 9,8. Magnesium ions are added to the DEA buffer to 
activate and stabilize the enzyme. During the reaction, alkaline phosphatase hydrolyzes 
the PNPP to form p-nitrophenol, which is yellow in alkaline solutions, and can be 
measured photometrically at 410 nm. The reaction rate follows zero-order kinetics. The 
units of activity can be calculated as micromoles of substrate hydrolyzed per minute, 
based on the molar absorptivity of p-nitrophenol. The kinetic reaction was performed on 
the Bayer Advia 1650 Chemistry analyzer.  
 
 
5.2.4 Gamma-gutamyl transferase (GGT) 
 
 
In the reaction with synthetic substrate (γ-glutamyl-p-nitroanilide), glycylglycine acts as 
an acceptor for the gamma-glutamyl residue and p-nitroaniline is liberated. The liberated 
product has an absorption maximum near 400 nm; the rate of formation is measured 
photometrically at 410 nm as a zero-order kinetic assay. The assay was performed on the 
Bayer Advia 1650 Chemistry analyzer. 
 
 
5.2.5 Alanine aminotransaminase (ALT) 
 
 
Alanine reacts with α-ketoglutarate under the catalytic influence of alanine                               
aminotransferase (in sample), while the decrease in NADH is monitored 
spectrophotometrically at 340 nm. The rate of decrease in absorbance is directly 
proportional to the ALT activity. The kinetic reaction was performed on the Bayer Advia 
1650 Chemistry analyzer. 
 
 
5.2.6 Aspartate aminotransferase (AST) 
 
 
Aspartate reacts with α-ketoglutarate under the catalytic influence of aspartate 
aminotransferase (in sample), while the decrease in NADH is monitored 
spectrophotometrically at 340 nm. The rate of decrease in absorbance is directly 
proportional to the AST activity. The kinetic reaction was performed on the Bayer Advia 
1650 Chemistry analyzer. 
 
 27
 
5.3 Polyacrylamide gradient gel electrophoresis (GGE) 
 
 
A modified polyacrylamide gradient gel electrophoresis method as described by Blom et 
al63 was used. This technique allows separation of lipoproteins by size. For LpB (LDL) 
electrophoresis a 2-8% acrylamide gradient was used and for LpA (HDL) electrophoresis 
a 4-18% gradient. Lipoproteins are stained with Sudan Black before the procedure. 
 
All LpB GGE electrophoreses were performed by Ms P Byrnes and all LpA 
electrophoreses were performed by Ms B Ratanjee. The gels were visually inspected. 
Previous experience was that VLDL and IDL gave broad bands in the mid (M) region 
between the origin and LDL bands on the LpB system. A sharp band in the M region was 
described as a focussed band: MF. This was previously found in hypercholesterolaemia 
ascribed to cholestasis. In the HDL gels, a band between “HDL2” and LDL suggested the 
presence of an unusual lipoprotein species. See Appendix A.1 for the complete 
methodology for LpB and LpA GGE. Figure 3 is a photograph of a GGE with MF bands. 
 
Figure 3: Representative GGE of LpX 
 
 
 
In lanes 3, 4 and 5 a MF band can be seen. The samples were from a patient with gallstones (lane 3) and a 
patient with head of pancreas carcinoma (lanes 4 and 5).  
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5.4 Cholesterol assay 
 
 
TC and FC were measured by a colorimetric method from Wako Chemicals GmbH, 
Germany, utilising microtitre plates for rapid reading of large numbers of samples.  
 
Cholesterol ester is hydrolysed by cholesterol esterase in the presence of water, to form 
cholesterol and a free fatty acid. All cholesterol is reacted with oxygen by cholesterol 
oxidase, to form cholest-4-en-3-one and hydrogen peroxide.  Two molecules of hydrogen 
peroxide react with 4-aminoantipyrine and DAOS in the presence of peroxidase to form a 
blue compound that absorbs maximally at 600nm.  
 
Free cholesterol is converted to cholest-4-ene-3-one by reacting with oxygen in the 
presence of cholesterol oxidase and this step produces hydrogen peroxide on a molar 
ratio with cholesterol.  Next, 4-amino-antipyrene reacts with phenol and uses hydrogen 
peroxide in such a way that a red quinone pigment is formed along with water. See 
Appendix A.2 for the complete methodology.   
 
 
5.5 Triglyceride assay 
 
 
Lipase hydrolyses triacylglycerol to free fatty acids and glycerol. The latter is converted 
to glycerol-3-phosphate by glycerokinase and adenosine triphosphate (ATP). The 
glycerophosphate is reacted with oxygen by glycerophosphate oxidase yielding 
dihydroxy-acetone-phosphate and H2O2. Two molecules of the latter are used by 
peroxidase as well as 4-aminoantipyrine and 4-Cl-phenol to generate quinoneimine HCl 
and 4H2O, yielding a pink-red colour read at 500nm (or 546 in Hg) in a 1cm path. A GPO 
PAP kit was used. See Appendix A.3 for the complete methodology. 
 
 
5.6 Bile acid assay 
 
 
An enzymatic method was used in which, in the presence of nicotinamide-adenine 
dinucleotide (NAD), 3α hydroxysterol dehydrogenase from fungi is used to create 3-oxo-
hydroxysterol and NADH. Then NADH and nitroblue tetrazolium (NBT) salt produce 
NAD and formazan. Formazan has a maximal absorption at 530 nm (still suitable at 
540nm), and the intensity of the colour is directly proportional to the amount of bile acid. 
Adding phosphoric acid can stop the colour generation. The assay is actually for 3α-
hydroxy-sterols and will thus reflect bile acid concentration as well as cholestanol 
concentration. An Adcock Ingram kit was used. See Appendix A.4 for the complete 
methodology. 
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5.7 HDL subtype assay 
 
 
The method devised by Gidez et al. is a dual precipitation method, in which apoB-
containing lipoproteins are first precipitated. HDL2 is then precipitated from the clear 
HDL containing supernatant. Cholesterol is then analysed in the first (total HDL) and 
second (HDL3) supernatants and HDL2 cholesterol is calculated as the difference between 
the two. See Appendix A.5 for the complete methodology. 
 
 
5.8 Agarose gel electrophoresis (AGE) 
 
 
A Beckman Lipoprotein electrophoresis kit was used. Serum samples (less than three 
days old) were used. Lipoproteins are separated by electrophoresis based on charge in 
agarose medium. Sudan lipid stain was used. The presence of a cathodic band or smear 
suggested the presence of LpX. See Appendix A.6 for the complete methodology.  
 
 
 
5.9 Phospholipid assay 
 
 
This enzymatic method involves the hydrolysis of phospholipids by phospholipase D, 
releasing choline and phosphatidic acid. The choline, in the presence of 2 oxygen 
molecules and water, by means of choline oxidase, forms betaine and 2 molecules of 
hydrogen peroxide. Two hydrogen peroxide molecules react with 4-aminophenazone and 
phenol to yield 4(p-benzoquinone-mono-imino)phenazone and 4 water molecules. The 
enzyme is a peroxidase. The absorbance is measured at 500 to 505nm. See Appendix A.7 
for the complete methodology.  
 
 
5.10 Statistical analysis 
 
 
Commercially available software packages were used. Spreadsheets were Excel 
(Microsoft) and Quatro-Pro (Corel). The database was Paradox 9 (Corel). Prism and 
GraphPad InStat were used for the statistical analyses.  
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6. RESULTS 
 
 
 
6.1 Selection of samples 
 
 
Not all analyses were possible on all samples as “left-over” serum from test tubes sent in 
to the laboratory for liver function tests were used. Patients were not approached for 
additional samples. 311 samples from 188 patients were analyzed. Samples with bilirubin 
> 40μmol/L were selected, comprising a group of 236 samples – called “entire cohort”. A 
“final cohort” of 141 patients was used for the statistical analysis, since the group of 236 
included repeat samples from some patients. These 141 samples were, according to 
sample size, selected for those with the most complete additional biochemical parameters 
for subsequent analysis for correlations.   
 
 
6.2 Descriptive statistics of the final cohort of 141 
 
 
The descriptive statistics of the final cohort is presented in Table 2. There was a wide 
range of ages. The age ranged from neonates to 85 years, with an average age of 43 years. 
The median was 46 years and standard deviation was 23 years.  
 
There was a wide range of total bilirubin values, but the values were generally not very 
high. Total bilirubin (n=141) ranged from 40 to 616umol/l, mean 143μmol/L, median 
92μmol/L, and standard deviation 121μmol/L.  
 
The conjugated hyperbilirubinaemia comprised a wide range but not all were suggestive 
of obstructive jaundice or cholestasis. The mean was 107 μmol/L, with a standard 
deviation of 100 μmol/L and a median of 69 μmol/L. 
 
ALP and GGT comprised a wide range but not all values were suggestive of canalicular 
induction. The mean ALP concentration was 353 U/L and the mean GGT was 310 U/L. 
 
ALT and AST concentrations also spanned a wide range, with some suggesting 
significant parenchymal cell damage. The mean ALT concentration was 325 U/L and the 
mean AST concentration was 278 U/L.  
 
Of the 188 patients in the original cohort serum cholesterol was only checked in 30 
patients (16%) by the attending clinicians. Total cholesterol was measured in the Lipid 
laboratory in 98 patients of the final cohort of 141. The total cholesterol concentrations 
were very low in general, with only a few hypercholesterolaemic samples: TC > 7.5 
mmol/L was present only in 12 patients. The mean TC concentration was 4.2mmol/L. 
Free cholesterol and phospholipid concentrations followed a similar trend. 
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The range of triglyceride concentration was wide but there were few subjects with 
significant hypertriglyceridaemia. None suggested the presence of chylomicrons. The 
mean concentration was 2.1 mmol/L.  
 
Total HDLC, HDL2C and HDL3C concentrations were generally low. The mean HDLC 
concentration was 0.58 mmol/L. 
 
The range of bile acid concentrations was wide with a few samples suggesting no 
hypercholanaemia. The mean concentration was 338 μmol/L.  
 
 
6.3 MF detection on LpB GGE and abnormal LpA GGE bands  
 
 
Of the “entire” cohort 80 (34%) LpB GGE patterns displayed MF and 75 (32%) LpA 
GGE patterns displayed an additional band that was larger in size than HDL2, while in 
the “final” cohort 44 (31%) LpB GGE patterns displayed MF and 33 (23%) LpA GGE 
patterns contained the additional band.  
 
No MF was seen in the few neonatal samples (8) analysed; all had unconjugated 
hyperbilirubinaemia. The youngest subject with MF was a 3-month old with a 
choledochal cyst. 
 
Comparison of the descriptive statistics, by 2-tailed Mann Whitney test, of the samples 
positive and negative for MF on LpB GGE showed several statistically significant 
differences – as shown in Table 3. In contrast, comparison of samples positive and 
negative for MF on LpA GGE showed no statistically significant differences – as shown 
in Table 4.  
 
The classical indicators of cholestasis, namely TB, CB, ALP and GGT were strongly 
associated with MF, whilst parenchymal cell damage markers (ALT, AST) were not 
associated. Bile acid concentrations were practically all markedly raised, but higher 
values were found with MF. Hypercholesterolaemia and hypertriglyceridaemia, high FC 
and higher PL were associated with MF bands but not HDL. The ratios of FC/TC and 
TC/PL were higher with MF. As expected, higher CB/TB was associated with MF. The 
ALP/GGT ratio was a little lower with MF, and ALP dominated over ALT in MF-
positive subjects.    
 
 
6.4 Retardation factor for MF 
 
 
The average retardation factor (Rf) of the MF seen on LpB GGE, relative to the B-
particle of LDL, was 0.59. This differs from VLDL which is usually seen at Rf 0.2 – 
0.45. The Rf of each individual patient was very reproducible, as shown in Table 5. 
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Table 2: Panel A. Descriptive statistics of the final cohort. 
 Age TB CB ALP GGT ALT AST TC 
n 141 141 140 134 134 134 134 98 
Minimum 0 40 3 36 9 6 20 0.68 
25% 
Percentile 
31 61 41 119 88 56 81 2.3 
Median 46 92 69 212 210 122 161 3.46 
75% 
Percentile 
61 201 152 466 428 284 316 5.26 
Maximum 85 616 491 1873 2163 2908 2280 16.5 
Mean 43 143 107 353 310 325 278 4.2 
SD 22.65 120.6 100.2 350.8 312.5 526.5 361.8 2.685 
  
Table 2: Panel B. Descriptive statistics of the final cohort. 
 TG BA HDLC HDL3C HDL2C FC PL FC/TC 
n 99 108 97 97 95 72 80 67 
Minimum 0.43 8 0.08 0.07 0 0.17 0.85 0.12 
25% 
Percentile 
1.1 65 0.33 0.19 0.07 1.24 1.96 0.44 
Median 1.6 186 0.48 0.31 0.14 1.87 2.75 0.6 
75% 
Percentile 
2.6 507 0.79 0.46 0.34 3.1 4 0.83 
Maximum 7.4 1873 1.5 0.9 1.1 9.8 17.87 1.47 
Mean 2.1 338 0.58 0.34 0.24 2.5 3.6 0.65 
SD 1.377 370.4 0.3622 0.2064 0.2485 1.921 3.124 0.262 
 
Table 2: Panel C. Descriptive statistics of the final cohort. 
 FC/PL TC/PL CB/TB ALP/GGT ALP/ALT TC/TB 
n 60 79 141 135 134 95 
Minimum 0.07 0.44 0 0.15 0.04 0.01 
25% 
Percentile 
0.58 0.92 0.68 0.73 0.79 0.02 
Median 0.75 1.17 0.79 1.29 1.76 0.04 
75% 
Percentile 
0.95 1.61 0.87 2.2 5.1 0.07 
Maximum 2.66 5.57 0.99 15.4 37 0.23 
Mean 0.8 1.37 0.73 1.84 3.9 0.05 
SD 0.4344 0.7912 0.2159 1.892 5.196 0.04156 
The unit of age is years; TB, CB and BA in μmol/L; TC, TG, HDLC, HDL3C, HDL2C, FC and PL in 
mmol/L; ALP, GGT, ALT and AST in U/L. Abbreviations: n number, SD standard deviation.  
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Table 3. A comparison of MF-positive samples and MF-negative samples according to 
LpB GGE. 
Parameter or ratio P-value MF positive: x±SD MF negative: x±SD 
Age 0.23 47±21.45 41.24±23.3 
TB 0.0003 208.5±158.8 109.1±77.26 
CB < 0.0001 171.9±125.3 72.8±61.03 
ALP  < 0.0001 545.5±430 248.8±248.7 
GGT < 0.0001 475.9±392.4 236.6±237.3 
ALT 0.77 269.0±467.9 365.5±560.5 
AST 0.34 292.3±398.5 280.3±349.0 
TC 0.0044 5.348±3.36 3.635±2.082 
TG < 0.0001 3.058±1.348 1.631±1.15 
BA 0.029 414.3±362.1 305.5±370.1 
HDLC 0.55 0.5197±0.3164 0.596±0.3796 
HDL3C 0.96 0.3431±0.2355 0.33±0.195 
HDL2C 0.33 0.1868±0.1797 0.2654±0.2684 
FC < 0.0001 4.028±2.666 1.816±0.97 
PL < 0.0001 5.663±4.415 2.63±1.37 
FC/TC < 0.0001 0.8272±0.1445 0.58±0.26 
FC/PL 0.161 0.9241±0.4887 0.756±0.41 
TC/PL 0.012 1.15±0.6757 1.46±0.82 
CB/TB < 0.0001 0.8384±0.09405 0.68±0.24 
ALP/GGT 0.035 1.416±1.242 2.07±2.14 
ALP/ALT 0.007 5.05±5.173 3.19±5.06 
TC/TB 0.149 0.047±0.05 0.05±0.037 
 
Table 4. A comparison of abnormal-positive samples from abnormal-negative samples 
according to LpA GGE. 
Parameter or ratio P-value MF positive: x±SD MF negative: x±SD 
Age 0.42 44.7±22.33 48.6±17.38 
TB 0.63 131.2±123.4 138.4±114.8 
CB 0.78 102.7±100.0 110.1±94.35 
ALP  0.65 297.8±256.1 376.2±391.1 
GGT 0.77 315.5±268.3 322.3±338.7 
ALT 0.44 334.2±493.6 349.0±566.8 
AST 0.88 288.0±341.6 299.4±391.5  
TC 0.32 3.75±2.39 4.34±2.8 
TG 0.053 1.63±0.85 2.3±1.5 
BA 0.38 288.8±305.5 361.9±393.6 
HDLC 0.101 0.64±0.34 0.53±0.36 
HDL3C 0.76 0.39±0.24 0.308±0.19 
HDL2C 0.87 0.25±0.26 0.23±0.24 
FC 0.35 2.18±1.78 2.57±2 
PL 0.99 3.33±2.2 3.76±3.4 
FC/TC 0.9 0.66±0.33 0.65±0.24 
FC/PL 0.27 0.76±0.59 0.82±0.38 
TC/PL 0.76 1.2±0.77 1.39±0.79 
CB/TB 0.74 0.77±0.12 0.77±0.16 
ALP/GGT 0.87 1.98±1.85 1.9±2.09 
ALP/ALT 0.55 3.3±4.4 4.06±5.6 
TC/TB 0.4 0.04±0.03 0.05±0.45 
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Table 5: Rf of MF found relative to B-species of LDL. 
Patient number Observed Rfs of repeated 
GGEs 
Average 
12 0.6;0.61 0.61 
18 0.42;0.42 0.42 
30 0.6 0.6 
50 0.67 0.67 
51 0.63 0.63 
52 0.63 0.63 
53 0.59;0.55 0.57 
61 0.6 0.6 
62 0.71 0.71 
65 0.56 0.56 
66 0.5 0.5 
69 0.52;0.71 0.615 
73 0.6 0.6 
74 0.58 0.58 
79 0.5 0.5 
81 0.53; 0.58; 0.44 0.517 
95 0.64 0.64 
96 0.7 0.7 
97 0.66 0.66 
101 0.68; 0.64 0.66 
104 0.71 0.71 
105 0.57; 0.56; 0.6 0.58 
107 0.62 0.62 
110 0.64; 0.73; 0.69 0.69 
111 0.48; 0.48; 0.5 0.49 
116 0.57 0.57 
124 0.54 0.54 
129 0.51 0.51 
131 0.54 0.54 
132 0.63 0.63 
139 0.53 0.53 
167 0.55 0.55 
171 0.51 0.51 
182 0.52 0.52 
183 0.57 0.57 
185 0.55 0.55 
187 0.67 0.67 
191 0.67 0.67 
192 0.6 0.6 
Total average ± SD  0.59 ± 0.07 
 
 
6.5 Relationship of MF to biochemical parameters 
 
 
In this unselected series of icteric samples, LpX can be expected to occur in increasing 
prevalence according to the hyperbilirubinaemia, hypercholanaemia, canalicular-enzyme 
derangement and hypercholesterolaemia. The relationship of MF on LpB GGE was 
evaluated in quartiles of TC, TB, CB/TB, ALP, GGT, ALP/ALT, FC, FC/PL, PL, FC/TC 
and BA, as depicted in Table 6. The approximate values of the quartiles can be found in 
Table 2. Reviewing the contingency table analysis results, the following conclusions can 
be made: 
 
TC was not linked to MF directly, although a trend appears to be the case. Samples with 
MF had a range of TC of 1-11mmol/L, while samples without had a range of 0.8-
16mmol/l. In the “final” cohort, where TC was > 7.5mmol/L eight out of twelve (66%) 
had MF, while where TC was < 7.5mmol/L 14 out of 86 (16%) had MF. Looking at the 
“entire” cohort, ten out of twelve with TC > 7.5mmol/L (83%) had MF. 2x2 Contingency 
comparison showed p<0.0006. Thus MF correlates well with severe 
hypercholesterolaemia. 
 
TB had to be > 40μmol/L for inclusion in the cohort. The contingency table showed a 
graded increase, with ± 50% MF positive if TB > 321μmol/L. Cholestasis is said to occur 
when CB/TB exceeds 0.3,76 but higher values suggest a greater impairment of CB 
excretion and are thus more suggestive of “obstruction”. Looking at CB/TB, 60% had 
MF positive if the ratio was > 0.9. The median was 0.84; 31/50 (62%) had MF positive if 
> 0.84 and 8/50 (16%) MF positive if < 0.84. 
 
Canalicular enzyme (ALP and GGT) induction is suggestive of cholestasis. ALP showed 
good predictive value for MF detection. Below the median (408U/L) 11/66 (17%) was 
positive and above the median 33/66 (50%) was positive. GGT showed similar results to 
ALP with 13/66 (20%) of results below the median MF positive and 30/66 (45%) above 
the median MF positive. The ALP/ALT ratio did not appear to govern MF positive 
samples. 
 
Since LpX contains only FC, the correlation of MF with FC was tested. FC concentration 
showed a linear relationship with the prevalence of MF: below the median 3/36 (8%) had 
MF positive and above the median 18/36 (50%) had MF positive. The FC/PL ratio was 
not associated with changes in the prevalence of MF. PL concentration above the median 
was positive for MF in 22/40 (55%), while 5/40 (12.5%) below the median was positive 
for MF. FC/TC ratio strongly influenced the prevalence of MF; as shown in Table 6. For 
FC/TC below the median (0.6), 0/34 showed MF, while 17/34 (50%) above the median 
had MF. 
 
BA was also correlated with MF prevalence. Below the median 13/54 (24%) were 
positive and above the median 21/54 (39%) were positive. If BA concentration was > 
65μmol/L 32/34 (96%) had MF.   
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The conclusions are that the high ratio of FC/TC (>0.6) is a strong determinant of MF, 
together with markers of cholestasis: TB, CB/TB, BA and ALP. 
 
 
Table 6: Contingency table of MF occurrence in quartiles of parameters. 
Parameter (n) Q1 Q2 Q3 Q4 χ2 
TC (98) 5 6 10 11 0.18 
TB (141) 6 6 8 18 0.0025 
CB/TB (141) 1 7 16 15 < 0.0001 
ALP (97) 7 4 13 20 < 0.0001 
GGT (97) 7 6 9 21 < 0.0002 
ALP/ALT (97) 8 9 10 15 0.256 
FC (69) 1 2 7 11 0.0006 
FC/PL (80) 9 8 7 3 0.2 
PL (80) 2 3 9 13 0.0004 
FC/TC (58) 0 0 9 8 < 0.0001 
BA (112) 2 11 9 12 0.008 
Q1, Q2, Q3 and Q4 indicate the quartiles in ascending order as defined in Table 2. The number of subjects 
in each parameter is indicated in brackets.  
 
 
6.6 Comparison of AGE and GGE 
 
 
In 43 patients agarose gel electrophoresis (AGE) was performed to compare LpX with 
the LpB GGE findings. As shown in Table 7, LpX was recorded in 19/43 subjects on 
AGE and 14/43 on GGE. In 84% of cases there was agreement between the LpB GGE 
and AGE; in 16% of cases a discrepancy was found between the two. This prompted 
closer analysis of the AGE. Six reports of AGE are dubious. There had been a bias to find 
LpX and there is no objective way to validate the pattern on AGE. 
 
Both patients 134 and 135 had true conjugated hyperbilirubinaemia (conjugated bilirubin 
> 30% of total), but with a relatively low ALP of 112 and 189 U/l respectively. In both 
the total cholesterol was extremely low, at 2.5 and 1.5 mmol/l, respectively. Patient 
number 136 had unconjugated hyperbilirubinaemia due to spherocytosis. It is very 
unlikely that LpX was indeed present in these patients. The AGE only showed the 
possibility of LpX – only a faint cathodic smear in each case, which could be due to 
differential background staining and staining is influenced by the wash-step. These 
factors do not affect GGE as staining takes place before the samples are loaded onto the 
gel. Likewise, in patients 173, 175 and 184, AGE showed a faint cathodic smear, but no 
convincing band of LpX.  Accepting that in 6 of 19 cases there was a low likelihood of 
LpX, the agreement of LpX by AGE and MF by GGE is very good. It should be noted 
that the samples analysed were not necessarily obtained in the fasting state and that 
chylomicrons may thus have caused some ambiguity in some patients’ samples. In only 
one patient (patient number 162) did the GGE show a MF band while the AGE did not 
suggest LpX. The patient had severe conjugated hyperbilirubinaemia and 
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hypercholanaemia. The discrepancy may be due to the fact that the total cholesterol was 
1.9 mmol/l in this patient and AGE may not be sensitive enough to detect LpX if the 
concentration is that low. 
 
 
6.7 Clinical correlates of MF on GGE 
 
 
The diagnoses of patients with MF on LpB GGE are shown in Table 8. Many died before 
a final diagnosis was made. Autopsies were not performed. 
 
The sample of the one subject with cholangiocarcinoma and MF negative on GGE was 
taken after a stent had been placed in the common bile duct, so no LpX would be 
expected. On GGE, only patients with sepsis and severe cholestasis on biochemistry had 
an MF.  Many patients with HIV/AIDS showed an MF. Possible causes include 
disseminated tuberculosis or other infiltrative parenchymal disease, drug-induced (TB-
therapy or antiretroviral therapy) or tumour infiltration, including Kaposi sarcoma. 
 
A clear MF was seen on GGE in all patients with undoubted extrahepatic obstructive 
jaundice, based on severe conjugated hyperbilirubinaemia, hypercholanaemia and clinical 
diagnosis. Causes were cholangiocarcinoma (8), common bile duct injury (1), 
choledochal cyst (1) and phlegmon obstructing the common bile duct (1). The other 
diagnostic entities most likely represent intrahepatic cholestasis.  Of the 12 cases with TC 
> 7.5mmol/L, 8 had undoubted extrahepatic cholestasis according to diagnosis, although 
not all had MF on GGE. 
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Table 7: Comparison of GGE and AGE findings. 
Patient 
Number 
AGE: 
Suggestive of 
LpX? 
LpB GGE: 
Suggestive of 
LpX? 
Age and Clinical background 
70 No No 9 months old; Short bowel syndrome, 
TPN-induced cholestasis 
121 Yes Yes 73; PTB-treatment, ? underlying liver 
disease 
130 No No 62; Multiple complications after 
CABG, ? Fucidin-induced liver disease 
134 Yes No 47; Alcoholic liver cirrhosis 
135 Yes No 46; Alcoholic liver cirrhosis 
136 Yes No 14; Congenital spherocytosis 
137 No No 56; Chronic cholecystitis 
144 No No 61; Jaundice secondary to sepsis 
145 No No 39; ?PTB treatment-induced cholestasis 
146 No No 32; Unknown diagnosis 
147 No No 48; ? PTB treatment-induced hepatitis 
148 Yes Yes 70; Chronic active hepatitis B 
149 No No 53; Alcoholic liver disease 
151 No No 18; Hepatitis A 
152 Yes Yes 30; Hepatitis A and TB treatment 
153 Yes Yes 35; Disseminated TB, HIV 
154 No No 31; Unknown diagnosis 
155 Yes Yes 42; Cholangiocarcinoma 
156 No No 27; Chronic active hepatitis B 
157 No No 60; Hepatitis secondary to sepsis 
158 No No 48; Fatty liver 
159 No No 76; Gall stones 
160 No No 50; Alcoholic liver cirrhosis 
161 No No 79; Alcoholic liver cirrhosis 
162 No Yes 58; Sepsis, CRF 
163 No No 85; Acute cholangitis 
164 No No 67; CA breast, liver metastases 
170 No No 45; ? Drug induced liver failure, HIV 
171 Yes Yes 57;?PTB-treatment-induced 
hepatitis/cor pulmonale 
172 Yes Yes 9; Hepatitis A 
173 Yes No 15; Cryptogenic cirrhosis 
174 No No 36; Hepatitis A 
175 Yes No 48; Alcoholic liver disease 
178 No No 53; Metastatic cholangiocarcinoma 
179 No No 74; Alcoholic liver disease 
180 Yes Yes 46; Stomach carcinoma with liver 
metastases 
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181 No No 70; Cholangitis 
182 Yes Yes 56; Cholangiocarcinoma, liver 
metastases 
183 Yes Yes 80; ? CA pancreas/cholangiocarcinoma 
184 Yes No Myocardial infarction 
185 Yes Yes Cholangiocarcinoma 
186 Yes No Head of pancreas carcinoma 
187 Yes Yes ? TB treatment-induced hepatitis, HIV 
  
 
 
 
Table 8: Most common diagnoses in MF positive samples. 
Diagnosis Patients MF positive Other patients with same 
diagnosis but MF 
negative 
Cholangiocarcinoma 8 1 
Sepsis 7 7 
HIV/AIDS 6 6 
Liver metastases 4 1 
Hepatitis A 3 6 
Gall stones 3 3 
Pancreas carcinoma 2 3 
Hepatitis B 2 4 
Common bile duct injury (MVA) 1 0 
Hepatocellular carcinoma 1 0 
Chronic pancreatitis, phlegmon 
mass obstructing common bile 
duct 
1 0 
Choledochal cyst 1 0 
TB pericarditis 1 0 
Acute alcoholic pancreatitis 1 0 
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7. DISCUSSION 
 
 
 
7.1 Summary of project and justification of LpX 
 
 
Although several methods to demonstrate and quantify LpX have been described over the 
past 50 years, few methods are easily performed in most routine laboratories. GGE may 
be a cheap, relatively easily performed test for laboratories to consider implementing. 
This study prospectively collected a series of icteric blood samples, documented 
parameters relating to cholestasis and LpX, and examined LpA and LpB GGE for 
patterns suggestive of LpX, creating the shorthand term of MF so as not to bias the 
interpretation. In the former gel system, unusual species of HDL-like lipoproteins did not 
correlate with any associations of MF, meaning these bands more likely represent altered 
HDL species rather than LpX. Since the MF in the LpB GGE had all the correlations 
expected for LpX and indicated particles in the size range for LpX, it can be concluded 
that the MF is indeed LpX.  
 
Although there are many techniques to describe LpX, none is regarded as a “gold” 
standard. LpX becomes an important entity in severe hypercholesterolaemia where it may 
be necessary to distinguish primary from secondary hypercholesterolaemia. About a third 
of the serum samples collected from jaundiced patients showed the presence of LpX on 
GGE.  
 
 
7.2 Detection of LpX 
 
 
LpX should rather be called lipovesicle X as it consists of a lipid shell with an aqueous 
core – unlike other lipoproteins. The aqueous compartment contains albumin and bile 
salts. The particle also contains some surface (apo)proteins. Techniques to demonstrate 
the particle range from ultracentrifugation to differential precipitation, to antibody 
recognition and electrophoresis. The latter could utilise any centrifuent to demonstrate the 
particle. Apart from ultracentrifugation, alternative methods were not available for this 
study. Sample volumes were too small and staff were lacking to pursue this further as a 
way to prove that MF is LpX.  
 
Lipid stains are generally sensitive and specific. In contrast to true lipoproteins, LpX has 
little neutral lipid and generally more polar lipids. This may limit its detection by a lipid 
stain. Protein stains are also sensitive and may be attractive provided that the background 
proteins have been cleared, as will be the case in GGE. Immunoassays, including 
Western Blot increase the complexity, duration and cost. If albumin is used for 
identification in Western Blots the assay may be less specific. If other epitopes on LpX 
are used they may not apply to all LpX and may still identify apoproteins. Owing to the 
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aqueous core, LpX is destroyed by freezing and may not reassemble on thawing. This 
means that samples with LpX cannot be frozen for demonstration of LpX by physical 
properties such as ultracentrifugation or electrophoresis. 
 
In this project, electrophoretic assays for large (apoB-containing) and small (HDL-like) 
lipoproteins were utilised. This technique was originally devised for separation of LDL 
species but was later found to be useful in the diagnosis of dysbetalipoproteinaemia. 
During the development, an unusual, narrow band was observed in some samples coming 
from jaundiced patients. Since lipoproteins are pre-stained with Sudan Black, the patterns 
can be read without distortion and without delay. Additionally, the ingredients are 
inexpensive, the sample volume required is small and samples can be kept for several 
days at 4-8ºC. Although the staining by Sudan Black is likely more intense in AGE, by 
virtue of dehydration, there is greater time required after electrophoresis to demonstrate 
LpX. Additionally, different properties are employed for the migration of LpX. In AGE 
there could be misinterpretation with chylomicrons whereas in GGE there could be 
confusion with VLDL1 or VLDL2. The Rf of VLDL1 is larger than the Rf demonstrated 
for MF (LpX) in this study, but VLDL2 may be confused for MF. Apart from the 
narrowness of the MF band of MF relative to VLDL2, other features could be useful to 
discriminate MF. VLDL is generally visible, when the (fasting) TG is > 1.7 mmol/l and 
in this setting the LDL species is generally modulated by cholesterol ester transfer protein 
(CETP) and hepatic lipase (HL) to a smaller “B” species. Sample numbers were too small 
to investigate using these features in the discrimination between LpX and VLDL in 
dubious cases, of which there were none in the eyes of an experienced reporter of the 
GGE method. 
 
 
7.3 The cohort of patients 
 
 
There was no particular selection of patients in this series that examined jaundiced 
patients in general. The samples came from investigation of in-patients and comprised a 
wide variety of disorders and biochemical parameters, making this study very applicable 
to everyday practice. In general, these were very sick patients but exact clinical states 
were not investigated in detail and final clinical notes were accepted as reliable. Severe 
disease and/or malnutrition are suggested by the high frequency of very low cholesterol 
concentrations. The commonest diagnostic settings for extrahepatic obstruction were 
cholangiocarcinoma, gallstones and carcinoma of the head of the pancreas. In cases with 
convincing extrahepatic cholestasis, GGE was suggestive of LpX in 100% of cases. The 
severe hypercholesterolaemia cases were found in the following diagnoses: 
cholangiocarcinoma (3), head of pancreas carcinoma (2), chronic pancreatitis (2), 
gallstones (1), sepsis (1) and hepatocellular carcinoma (1).   
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7.4 Correlations of LpX  
 
 
The exact mechanism(s) at play in the pathogenesis not being known, known correlates 
were examined in this study. CB, ALP, GGT, FC, PL, FC/TC and CB/TB are all good 
predictors of LpX. TC concentration was not statistically significantly correlated with the 
finding of LpX, presumably because of the high variability of the TC results. Samples 
suggestive of LpX had a range of TC of 1-11mmol/l. There were many patients with a 
very low TC, fitting in with the serious clinical diseases present in the cohort. It is not 
known whether significant or severe hypercholesterolaemia preceded the 
hypercholesterolaemia, permitting the formation of LpX, which persisted, or whether 
LpX can form even in the presence of low plasma cholesterol. At such low TC levels it 
would have been interesting to see if acanthocytosis, associated with chronic 
hypocholesterolaemia, was detected, but it was not checked for at the Haematology 
Laboratory. Where TC was > 7.5mmol/L eight out of twelve (66%) had LpX, while 
where TC was < 7.5mmol/L 14 out of 86 (16%) had LpX. FC/TC was the best predictor 
of LpX; unfortunately FC is not commonly available test. About 50% of samples had 
LpX if TB was > 321μmol/L, suggesting that severe impairment of biliary excretion 
could suffice for the formation of LpX. From this study it would appear that 
hypercholesterolaemia, hypercholanaemia of > 65 μmol/L and severe 
hyperbilirubinaemia are the appropriate constellation for finding LpX. 
 
 
7.5 Clinical implications 
 
 
Of the 188 patients in the original cohort serum cholesterol was only requested by the 
attending clinicians in 30 patients (16%), even though obstructive liver disease is a 
known cause of secondary hypercholesterolaemia. In cholestasis the secondary 
hypercholesterolaemia (due to LpX) may cause xanthoma, peripheral neuropathy, renal 
disease, pseudohyponatraemia, hyperviscosity syndrome and possibly atherosclerosis. 
Especially in patients with long-term cholestasis, it is therefore important to perform a 
fasting lipogram and to make physicians aware of the association with LpX and the 
potential complication of hyperviscosity, and to be cautious about interpreting sodium 
concentration. The most accessible diagnosis of LpX for the clinician is an 
electrophoretic procedure, with the agarose gel electrophoresis as this is conveniently 
commercially available as a kit. In high turnover laboratories GGE may be cost-effective.   
 
 
7.6 Limitations of the project 
 
 
Criticisms of this project can relate to the lack of validation of LpX by ultracentrifugation 
or other described methods, imperfect descriptions of the time course of LpX, deriving 
the best predictors for LpX by combinatorial techniques of biochemical and clinical 
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parameters, prognostic implications and alternative techniques of demonstrating LpX that 
could be more informative. 
 
As previously stated, sample volumes were inadequate for ultracentrifugation. This 
procedure would also have been further limited by availability of staff. Similar 
constraints would apply to precipitation techniques. The small number of subjects with 
LpX and the limited follow-up period mitigated against detailed predictive and 
prognostic analyses. 
 
In order that LpX can be derived by more conventional laboratory assays, it may have 
been worth following the approach of Blom et al77 for dysbetalipoproteinaemia where the 
cholesterol/apolipoproteinB (apoB) ratio was informative of the kind of lipoprotein that 
had accumulated. The ratio of TC/apoB may distinguish hypercholesterolaemia due to 
high LDL-C from hypercholesterolaemia due to LpX. Since LpX does not carry apoB, a 
high TC:apoB ratio would suggest the presence of LpX.  
 
 
7.7 Future studies 
 
 
Several avenues of investigation are still of interest for LpX and this technique of 
demonstrating LpX.  
 
Apart from comparing the MF with ultracentrifugal or differential precipitation for 
sensitivity of detection, the GGE method could be further investigated for better detection 
and/or discrimination from other lipoproteins. For example, proteins or phospholipids 
might be able to enhance the detection, as they are richer in LpX than similar-sized 
lipoproteins. A simple precipitation within the gel, of unstained plasma, could produce a 
precipitation of albumin in LpX (but not other lipoproteins) by using SSA or TCA. These 
procedures are quick. Whilst a protein dye such as Coomassie Blue may appear 
attractive, it requires a period of destaining, or, at low concentration, prolonged 
incubation. Using amido Schwartz in the electrophoresis buffer could be considered but 
is not likely to be sensitive. Victoria blue could be used to demonstrate phospholipids and 
could enhance the colour of phospholipid. But it will extend the time to making a 
decision. Fluorescent stains that integrate into phospholipids may be evaluated but they 
might not be practical. As glass does not transmit UV light, some dyes might require 
analysis outside the assembly. In any case, this approach would also require more 
sophisticated equipment than is generally available in routine clinical chemistry 
laboratories. The detection of bile salts may be limited by sensitivity or loss of the bile 
salts by diffusion.  
 
Factors influencing the Rf of LpX might yield some insight into the pathophysiology of 
its formation. Furthermore, the clearance of LpX could be of interest: most likely the 
particle will retain its diameter whilst its concentration recedes after a curative 
intervention such as decompressing an obstructed biliary tree. Investigations should be 
done to determine the optimal storage conditions and time to analysis for LpX by GGE. It 
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is of interest to prevent disruption by freezing. Here dimethylsulphoxide or glycerol may 
be useful.  
 
If possible, an examination for LpX should be performed in LCAT deficiency and 
parenteral nutrition to evaluate the LpX detection and characteristics in these conditions. 
The impact of cholestasis on lipoproteins in the LpA GGE is also of interest and may 
merit more detailed investigation.    
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8. CONCLUSION 
 
 
 
Lipoprotein X is an abnormal “lipoprotein” that has been investigated since the early 
1950s, but many questions still remain unanswered. The mechanism of 
hypercholesterolaemia in obstructive jaundice is not yet completely clear. The exact 
mechanism of formation of LpX is still unknown. Although LpX initially received much 
attention as a possible test to investigate the aetiology of cholestasis, the practical utility 
of this biomarker has been disappointing.  
 
This study showed that the non-denaturing polyacrylamide gradient gel electrophoresis 
system (2-8%) is a useful test in demonstrating LpX. Although CB, ALP, GGT, FC, PL, 
FC/TC and CB/TB are all good predictors of LpX, and FC/TC is the best predictor of 
LpX a direct demonstration of LpX is still preferable. In the setting of obstructive liver 
disease LpX is seen in 66% of patients if TC is > 7.5 mmol/L and here it could be a 
useful way of discriminating an underlying condition such as familial 
hypercholesterolaemia from hypercholesterolaemia associated with cholestasis. The 
detection of LpX may also have application in suggesting LCAT deficiency. 
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APPENDICES 
 
 
 
Prof Marais kindly provided the standard operating procedures of the Lipid laboratory 
here attached for interest. 
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Appendix A.1 
 
 
NON-DENATURING GRADIENT GEL ELECTROPHORESIS 
 (GGE) FOR LP 
 
 
GENERAL 
 
 
The technique of non-denaturing gradient acrylamide gel electrophoresis allows 
separation of lipoproteins (LP) by size. The LP may be demonstrated by staining lipid or 
protein. Pre-staining the sample with a lipid stain allows specific visualisation of 
lipoproteins in the original glass sandwich while protein staining has to be done after 
removing the gel and is only specific for large, apolipoprotein B-containing lipoproteins.  
Separation of CM and VLDL is difficult because of the size of these LP and these 
triglyceride-rich lipoproteins are seen as broad size ranges.  The IDL range is also not so 
distinctly separated. Gels may be selected to demonstrate LpB series (LDL) and LpA 
series (HDL). A 2-16% gradient is usually recommended for LDL and for HDL, 4-30%1 
but the Lipidology laboratory of the University of Cape Town uses a mini-gel of 2-8% 
acrylamide gradient for LpB, and a 4-18% for LpA. 
 
Qualitative differences in LDL may be important. The first relation between smaller 
denser LDL and heart disease was shown by Melissa Austin et al, who recognised two 
types of LDL.2 Dormans suggested that 3 LDL subtypes could be identified by either 
ultracentrifugation or GGE, although the latter method could on occasion identify 5 
bands.3 Tashiro found a "midband", which is probably Lp(a), that predicts heart disease 
in FH subjects.4 Similarly, HDL3 and HDL2 subtypes may influence atherosclerosis. The 
GGE and HDL ultracentrifuge subtypes have not been compared yet in this laboratory. In 
this system, small dense LDL can be demonstrated in the lowest quintiles of triglyceride, 
waist/hip ratio, body mass index and fasting glucose concentration. However, small dense 
LDL is seen usually at a triglyceride concentration of >1.7mmol/L, and almost always at 
TG >2.5mmol/L. Similarly, a waist/hip ratio of >1, BMI >30 or glucose >7mmol/L is 
highly associated or with small dense LDL.  It has been shown that a TG/HDL-C ratio, in 
molar terms, of >1.33 is also strongly predictive of small dense LDL.5 The system is also 
good for diagnosing dysbetalipoproteinaemia.6  
 
Samples may be plasma or serum or isolated lipoproteins. Samples should immediately 
be placed on ice and processed as soon as possible, but have been satisfactory for LDL 
characterisation up to 1 week when stored at 4°C, either stained immediately or after a 
delay.  The samples can be frozen at -20°C for a few weeks, and for several (>12) weeks 
at -80°C. There is a factor in the lipoprotein-deficient serum (LPDS) that can increase the 
size of LP on incubation. It is heat labile and dialysable but is neither CETP nor 
phospholipid transfer protein (PLTP). 
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Samples from animals with cloven hooves may carry foot and mouth disease virus. 
Samples can be sterilised by heating to 56°C for ≥30 minutes. This has been tested and 
shown not to affect human samples. After processing the same samples, they should be 
placed at pH <6 or >9.   
  
 
MATERIALS 
 
 
SUDAN BLACK STAIN. 1% Sudan Black is added to ethylene glycol. Filter the 
solution. It keeps for several weeks.  
SATURATED SUCROSE with a spatula tip of bromophenol blue. 
SOLUTIONS FOR SDS-PAGE as declared in the laboratory methods but omit SDS from 
all. Fresh acrylamide solution is better for clarity of separation. Depending on the brand 
and batch of acrylamide slight adjustments may need to be made for optimal perfomance, 
adjusting the denser solution to 7 to 8%.  
NILE RED STAIN. Dissolve 1mg in 100ul of dimethylsulphoxide (DMSO) as a stock 
solution (50X), then dilute by adding 2ul to 98ul of DMSO for use on GGE. Add 10μl to 
50μl of plasma.  This stain with similar sensitivity to Sudan Black but requires UV light 
exposure for visualising the lipoproteins.  
 
Store Minigel apparatus and powerpack in cold room or refridgerator. 
 
 
PROCEDURE LDL FOR  (LpB) GEL 
 
 
Cast a 2-8% polyacrylamide gel and a 3% stacking gel with a minimal but definite layer 
of gel between the bottom of the wells and the separation gel. Mostly 2 gels are run in the 
system, with 15 lanes per gel. Label the glass plates. (The stacking gel may be coloured 
by a small amount of phenol red to make loading easier.) 
 
To 100ul of plasma add 50ul of lipid stain, mix and incubate for a minimum of 1 hour at 
4°C. Spin for 20 minutes at 10000G. Mix an equal volume of supernatent with saturated 
sucrose and load approximately 12ul per well. 
 
Prefocus the gel at 20V for 30 minutes. This is ideal but not essential. Run the gel at 
130V for 18-24 hours.  The progress is visible! Remove the glass sandwich from the 
stand, dry with a paper tissue. 
 
Recording of the gel:  Write the gel identification on the dry glass plate. Mark the point at 
which the separation and stacking gels meet by placing a dot next to the spacer.  The gel 
is now placed facedown on a photocopy machine and covered with white paper before a 
photocopy is taken. Afterwards, photograph the gel if necessary. The gel can also be 
scanned in the Hoefer densitometric scanner while in the glass plates, or it may be 
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recorded on the Biorad Geldoc videocamera.  Hereafter it is dried on filter paper or 
cellophane.  
 
 
PROCEDURE FOR HDL (LpA) GEL 
 
 
Cast a 4-18% gradient gel and a 3% stacking gel. Prepare the plasma sample with Sudan 
Black in ethylene glycol as for LpB GGE but load directly, 16ul/lane.  
 
Prefocus the gel at 20V for 30mins, run at 130V for 4 hours.  The progress is visible! It is 
analysed in the same way as the LpB GGE. 
 
 
INTERPRETATION OF LpB GGE 
 
 
REPORTING 
 
 
The gel is inspected without knowledge of clinical or biochemcial detail. Comment 
should be made about material in the stacking gel as occasionally there may be 
significant precipitate in the stacking gel, either from granules of Sudan Black that were 
not removed by the spin, or from lipoprotein aggregates.  The origin (top or least dense 
part) of the separation gel reflects the largest particles. The minigel is about 60mm long. 
In the system the stain reflecting lipoproteins in the LDL density range, is from 
approximately the junction of the top 2/3 with the bottom 1/3. The chief LDL-related 
bands are in the bottom 1/6 of the stained area. 
 
 
TERMINOLOGY 
 
 
The gel is described by simple terminology avoiding terms inferring separation by 
density. Since the gel was developed to look at “LDL”, the zone between the origin and 
the LDL being referred to as "mid" and staining in this region was consequently referred 
to as M, which was later modified according to an earlier or later observation to M-early, 
or M-late to describe particles that were respectively larger or smaller. Subsequently it 
became clear that chylomicron-like particles tended to remain at the origin of the 
separation gel, and hence were termed O. At the “LDL” range, the largest particle is 
designated "A" while some intermediate "I" bands may be discerned or the "B" band as 
the smallest (densest) LDL which has been associated with a higher risk of ischaemic 
heart disease in FCH and with hypertriglyceridaemia. These common species of A and B 
appear to agree with the prevalences of A and B reported in most studies although they 
have not been specifically prepared. Subsequently it became clear that even further size 
distinctions can be made, now abbreviated to A-early, A/I, I/B and B-post. Sometimes a 
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band between A and M-late could be discerned, and referred to as pre-A. This band 
specifically disappears on adding a reducing agent, proving it is Lp(a). A small letter is 
used to designate that the band stains faintly, and a capital letter is used to demonstrate 
dominant bands. A sharply focussed band in the M-early range is seen in cholestatic 
jaundice, and is referred to as M-focussed (MF). 
 
Describing particles from large to small on this gel would thus be: O, M-early (Me),  M-
focus (MF, in Me range usually), M-late (Ml), pre-A, A-early (Ae), A, A/I, I, I/B, B, B-
post (Bp). Chylomicrons correspond to O, VLDL1 (Sf 60-400) to Me, LpX to Mf, 
VLDL2 (Sf 20-60) to Ml, pre-A is Lp(a), Ae to Bp are all species of LDL. 
 
 
RELATION TO DYSLIPIDAEMIAS AND FREDRICKSON TYPES 
 
 
All hypertriglyceridaemias give rise to staining in the M region.  In type I and IV and V 
there is intense staining of the M region, often with something visible near the origin and 
the LDL bands are often only slightly visible, if not absent.  In type III 
dyslipoproteinaemia the band peaks in the M range, with minimal LDL banding and there 
may be some staining at the origin. 
 
Hypercholesterolaemias will stain mainly the LDL range with some entry into the Ml 
region if IDL is present.  The LDL-A pattern is seen in most normal persons and 
hypercholesterolaemias, including FH, in which there is no hypertriglyceridaemia. Thus 
in normal and Fredrickson IIa one expects large species of LDL. In type IIb it would 
appear that almost always there is the in mid-portions, particularly Me, indicating an 
excess of VLDL-like LP. The LDL particle size in X-linked icthyosis is large, so that 
agarose gel electrophoresis to demonstrate fast-migrating beta-lipoprotein is still 
preferable to prove this diagnosis. 
 
The situation of Lp(a) is preA. LpX is seen in the M zone, usually as a sharp band and the 
distinct impression is that it is detected more sensitively than in agarose electrophoresis. 
LpX often gives the Sudan Black a greenish tinge. 
 
The colour of the lipoproteins can vary considerably from brown to blue, and the 
sharpness of the bands is much better with fresh acrylamide.  Lipid staining of isolated 
lipoproteins is also more intense than the staining in whole plasma. 
 
 
CALIBRATION OF LpB GGE  
 
 
Currently there is no standardisation for assays of small or dense LDL.  Small, dense 
LDL can be demonstrated by density (ultracentrifugation), or size (non-denaturing 
polyacrylamide gradient gel electrophoresis (GGE) or size exclusion chromatography 
such as FPLC). The reported size of LDL varies, with a slightly broader range reported 
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between 21 and 29 nm.7 The acrylamide gradients can vary.8 Nuclear magnetic resonance 
can detect lipoproteins by unique emission signals according to their mass, allowing the 
discrimination of up to 15 lipoproteins with estimates for LDL at 19 to 22nm.7  
Ultracentrifugation uses a few ml of fresh plasma and permits compositional analysis but 
takes hours to days and gravitational forces may cause the loss of some apoproteins.  
Typically, three fractions are separated:  LDL-I at 1.025-1.034g/ml, LDL-II at 1.034-
1.044g/ml, and LDL-III 1.044 - 1.060g/ml.9 The concentration can be reported as 
lipoprotein mass or protein or cholesterol. 
 
It has not been possible to calibrate the system accurately so that the diameter of the 
particles can be properly calculated. Currently we readily identify A and B patterns 
amongst the 15 lanes and use one of each LDL type to carry across from gel to gel to 
bring some standardisation about. Lanes 7 and 8 contain an A and B species that are 
repeatedly used from gel to gel for a few weeks, but mixing them is not a good idea as 
some changes in size can occur. The observation is also that small LDL can enlarge with 
time. Of course gels that are prepared individually for each run are not exactly 
reproducible. However, it has been found that the classification is extremely reproducible 
on repeat samples. 
 
Latex beads tended to clump and cause “ladders” and were thus not useful. We have 
generelly accepted that LDL particles will have the typically published diameters and that 
there is a broad size range for all other particles. There is even disagreement in diameters 
for LDL from different laboratories using size markers, and also with other methods of 
determining lipoprotein particle size. This makes accurate diameter determinations less 
useful. The gel is primarily used in this laboratory to describe patterns of major 
dyslipoproteinaemias involving apolipoprotein B-containing lipoproteins with particular 
reference to dysbetalipoproteinaemia and lipoprotein X, and to determine LDL particle 
size categories and whether there are significant changes in these as a result of 
interventions.  
 
Retardation factors. The system has been standardised against ultracentrifugally 
prepared VLDL1 (Sf 60-400), VLDL2 (Sf 20-60), IDL (Sf 12-20)  and LDL (Sf 0-12) . 
Taking the B particle as Rs=1.0, the following Rs values are typically found for V1: 0.2-
0.45. For V2 the Rs is 0.45-0.7; for IDL it is 0.7-0.85 and for LDL A-B it will be 0.85-1.0 
and about 1.05 for B-post.  
  
 
DIAGNOSTIC ASPECTS OF LDL GGE  
 
 
Hypertriglyceridaemias have M bands, and usually B or B-posts. In chylomicronaemia 
there is usually no LDL bands.  Mixed hyperlipidaemias also have M bands. 
Dysbetalipoproteinaemia has a preponderance of Ml band with very little or no LDL 
bands, although in some instances the pattern may change to only a LDL band in this 
condition upon successful therapy. If there is a lapse of dietary and drug compliance, the 
lipoproteins may decrease in size. Most hypercholesterolaemias have A bands, sometimes 
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I bands and occasionally there is a B band; the B usually being associated with a M or m. 
This pattern is almost the norm when the fasting triglyceride concentration is 
>1.8mmol/L, or waist hip ratio is more than 0.95. It is also prevalent in diabetics, but 
more so in men. PreA is seen variably and generally correlates with an apo(a) 
concentration of >50mg/dl, and some size variation can be seen. There is a distinct 
impression that LDL particles distribution distribute more strongly to a single species 
compared with ultracentrifugally derived subfractions.  In a population survey, it was 
found that about 2% of adults have no visible LDL bands, and about 2 % have 2 distinct 
bands, sometimes of equal intensity. Occasionally there may be more than 2 bands visible 
in the LDL zone. Interventions that modulate triglyceride concentration will usually alter 
LDL size at between 2 and 3 weeks. An interesting pattern of smearing through the preA 
region into the LDL region has not been explored. 
 
 
INTERPRETATION OF THE LpA GGE 
 
 
REPORTING 
 
 
This is done blinded and after selecting from the many lanes, likely equivalents of HDL 2 
and 3 species. The bands tend to be poorly staining and broad, and only occasionally can 
speciation be distinguished in the two regions. The LDL bands at the top may be 
classifiable as A or B but are often inadequately separated for comment.  
 
 
TERMINOLOGY OF "HDL GEL" 
 
 
Particles relating to HDL2b and HDL2a as well as HDL3a, HDL3b, HDL3c are 
described in the review by Silverman.10 In the present system we find mostly 2 peaks, 
one with Mr of 135kD and another at about 165kD. The former appears to be HDL3 and 
the latter HDL2. In some patients there is a smaller size lipid-staining peak, at about 
115kD. In some instances larger particles are seen in hyperalphalipoproteinaemia; in one 
patient discrete bands at 209, 229, 269, 300 and 365kD. 
 
Current practice is to assume that the common species of smaller size is HDL3, the larger 
is assumed to be HDL2. The description is thus of the intensities being dominant in either 
one of the two bands or equivalent. This agrees remarkably well with the area under the 
curve and the peak intensities on the gel scanner. Occasionally there may be small 
species of lipoproteins, to which the lable HDL4 has been given, or larger species to 
which the lable HDL1 has been given. These can range to a size close to the LDL band. 
Typically the Me, B pattern of the Lp GGE has only a HDL3 band on the LpA GGE.   
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STANDARDISATION OF PARTICLE SIZE 
 
 
This has not been satisfactorily performed yet. Usually the pattern can be described by 
comparison with the other 14 lanes on the same run. Latex beads of defined diameter do 
not provide a single neat band on the LDL or HDL system, while on the HDL system the 
rainbow markers do not give neat bands when undenatured. Protein staining on our 
system would be confusing especially in the HDL range as there are many proteins at 
these sizes.  
 
The utility of using haemoglobin (Hb) is under investigation. Hb has a molecular mass of 
64 458 and binds to haptoglobin (Hp) which has 2 binding sites for Hb. Hp is present in 
most individuals but rarely the Hp 0-0 status or anhaptoglobinaemia is found. The 
molecule is a tetrad of two a and b units. The a units can be a1 or a2 and slow and fast 
migrating forms of a1 are known. Several phenotypes of Hp are known: Hp 1-1 (a1a1b2) 
with mass of 80dk, Hp1-2 (a1a2b2) with a mass of 120kd and (a2a2b2) of 160kd. The Hp 1-
2 and 2-2 phenotypes can dimerise to 200 and 400kd forms.  Assuming one Hb to be 
bound per molecule, red bands should be seen on the GGE at 65, 145, 185, 225, 265 and 
465kd. It is difficult to prepare suitable plasma samples to act as distinct markers, but 
sometimes haemolysis leads to these bands being visible in the HDL gels. 
 
An unusual ladder of proteins has been observed between HDL and LDL on the HDL 
gels from some subjects in the coronary care unit. The calculated molecular mass seems 
to escalate approximately 300kd intervals up to 2.5 million molecular mass.  
 
 
APPLICATIONS 
 
 
FLUORESCENT STAINING. The preliminary observations suggest that pre-staining the 
plasma lipoproteins with Nile Red is as sensitive as Sudan Black staining for the LpB and 
LpA gels, but some optimisation is still required. There is intense staining at about 70kd 
on the LpA system which is not seen with a gel containing only albumin. 
 
COOMASSIE STAINING.  After the gel is run, it can be removed and placed in 
Coomassie staining solution according to laboratory protocols. If the plasma had not been 
pre-stained with Sudan Black, the LDL band is faint and possibly the preA band is more 
visible. Prestaining with Sudan Black enhances the Coomassie staining. Protein bands are 
visible below the LDL zone, at the edge of the gel and represent macroglobulins.  
 
SILVER STAINING. This method becomes very sensitive for detecting protein and a 
decent band of LDL is seen with about 4μl of plasma in the lane. There is little protein 
visible in the lipoprotein range.  Sudan Black enhances silver staining in a similar way 
that it enhances Coomassie staining and makes the entire range of lipoproteins from LDL 
to IDL stain very darkly. Acetone exposure of the gel for 30 minutes sensitises the 
unprestained LDL to silver. 
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WESTERN BLOT. This allows transfer to nitrocellulose and probing for apoproteins. 
The transfer of apoB is slow owing to its molecular mass and can be enhanced by adding 
SDS if lipids are not desired in further studies. 
 
 
ANALYSIS ON GELDOC 
 
 
The Biorad Geldoc apparatus allows convenient graphic recording of gels stained with 
visible dyes or of light emitted from fluorescent stains upon UV illumination. The system 
includes a personal computer, a videocamera mounted in a photographic black chamber 
with illumination facility, and a dedicated printer for images.  The graphics files are 
saved in C: under directories created for the staff, and in file names that can trace the gel 
efficiently. The graphics file stored can be used to print images and to analyse selected 
portions of images directly on the screen or by transferring the data to other software as 
x,y coordinates. This latter process affords better analysis and interpretation, especially 
through Graphpad Prism. The University of Cape Town Information Technology has 
been unable to link the Windows NT system to the network and the files have to be 
manually transferred by stiffy disk from the Geldoc to other personal computers. This 
also poses problems for back-up. 
 
 
CAPTURING THE GEL 
 
 
Switch on the computer, the video camera and the printer. The computer will prompt 
signing on as the administrator and the password.  
 
Select Multi-analyst Shortcut from the programme icons by a double click.  The display 
will have toolbars available but no image will be seen until one is created or recalled 
from stored files. To create a new image, go to File and select New. The videocamera 
view will now be on the screen.  
 
Dry the gel with a tissue and make certain there are no avoidable marks on the gel. It is a 
good idea to place a dot against the left and right spacers so that the junction of 
separation and stacking gels can be marked for reference during analysis. 
 
Go to Set-up. Enter the appropriate light source (white light for GGE with Sudan Black).  
Prepare the photographic chamber. Note that a white transforming plate is placed over the 
UV source for analysing gels stained with dyes absorbing in visible wavelengths. Place 
the gels appropriately on the white plate or on the glass for UV analysis. Close the 
chamber. Adjust the aperture, focus, and zoom of the camera. 
 
Make certain that the background density is uniform (best on analytical setting at the 
switch on the bottom front of the camera box).  Once set up, the image needs to be 
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captured.  Select Capture button at bottom left corner. This button may be masked by the 
lower edge of the screen, in which case click on the edge and drag it lower to display this 
button. Additionally click on View and remove the toolbar to allow the capture button to 
come into view.  The capture process will prompt the file saving data: In the Save As 
windown, select the “Work” folder, double click on the appropriate “Name” folder and 
enter the appropriate Subfolder and file name. Enter the file name and save as a *.bif file.  
 
Switch off the video camera (both the UV source and camera). To exit, select File, exit. 
To switch off the computer, go to Start, select shutdown and machine will close the 
programme and declare when it is safe to switch off manually.  
 
 
PRINTING THE IMAGE 
 
 
This can be done from the video camera while the gel is being recorded, or from a saved 
image.  In both cases the picture will include the surrounds of the gels unless there is 
appropriate cropping.  
 
With the programme activated, select the saved image: go to File, select Open, select 
Work, follow directory through Folders and then select the appropriate File. The image 
will be displayed, but should be maximised for better viewing.  Now select from the 
toolbar the open square to perform cropping so that the gel only is displayed, by clicking 
in one corner and dragging the mouse to enclose the area of interest. Take the mouse’s 
cursor to the Image button and select Crop. Now return to File, select Videoprint. Now 
press the button attached to the printer.    
 
 
ANALYSING THE GEL 
 
 
With the Multi-Analyst software activated, select the file from the appropriate 
subdirectory. The image will be displayed on the screen, best maximised. Select lanes to 
be analysed with care. The toolbar contains a button with a folded image for single lane 
selection. Click on this and then click the mouse to the appropriate point in the gel, 
typically at the left top of the lane to be analysed, and drag the mouse to the right and 
bottom of the portion of interest. Select the display in profile to view the lane as a 
densitometric scan, with optical density on the vertical axis and cm migration on the 
horizontal axis. If several lanes are to be analysed, use the “Selector” button which will 
place a “+”on the gel after which pressing “F” on the vertical toolbar will find lanes 
automatically. Select sensitivity required, usually at mid-point. The bands thus selected 
are demarcated in red. The profile can be viewed by pressing “View Profile”on the 
horizontal toolbar. To include all the selected lanes, go to “View”on main toolbar and 
select “Show all lanes”.  
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With the scan profile image box on the screen the saving can proceed.  From the File 
Menu select Export to Excel and select Active Window.  Now open Excel and scroll far 
right across to columns until reaching the columns containing numerical values and 
labelled “cm” and   “OD” for migration (x axis) and optical density (y axis). Select, copy 
and paste these 2 columns into a new Excel worksheet. This must now be saved as a text 
file (*.txt), onto a stiffy disk. On closing down the Multi-Analyst file, the process will 
request saving the changes (analyses and manipulations). Do not save these changes, as 
they will alter the original gel record. 
 
Activate Graphpad Prism, go to Files and select Import. Select the *.txt file on the stiffy 
drive or directory and proceed to import. Prepare a profile tracing by making a graph 
from the data sheet, best displaying the image as a line without the approximately 250 
data points. The baseline correction can be done according to a personally selected value 
by using the Analyze and then Transform selections, or by going to Remove Baseline. 
The data may also be pruned to the appropriate rows by selecting Analzye and Prune.  
 
The lane is analysed with retardation standardised to the given B distance for the 
particular run from which it is derived. Retardation is standardised according to the B 
band, Rf(B) = 1.0. Peak particle size can be described as a Rf.  The profile should be 
analysed for area under the curve with the baseline subtracted.  
 
 
ANALYSIS ON HOEFER SCANNER 
 
 
The first densitometric scanner for GGE scanned about a 1000 points as x,y coordinates 
at absorption of 595nm as it was originally designed for Coomassie stained SDSPAGE. It 
was found suitable for Sudan Black and thus was used for capturing data. Dr D J Blom 
developed the method below for capturing the data and processing it in Graphpad Prism. 
Locate the scan desired on the stiffy disks, bearing in mind that each scan is a single lane.  
Open the file using Notepad. Choose Edit and select all data. Select Edit again and do 
Copy command. 
 
Open Prism and prepare a datasheet which will receive the y coordinates. Paste the data 
to the Y column.  Create a serially numbered column in the X-axis starting at point 1 and 
using increments of 1 (column dialogue box is found under Change).  This procedure will 
create a graph.  
 
Manipulate the data via Analyse and Transform command to Prune Rows. Exclude the 
first 100 points according to judgement about the start of the separation gel.  Optionally, 
prune the rows again, by averaging 4 consecutive points.  Now copy the y-data to a new 
data sheet in which X starts at zero in a series.   
 
To convert the data to retardation factors, create a data sheet that will span from 0 to 1.1. 
Compare the marker and other lanes in the photocopy of the gel for A and B markers and 
ascertain the Rf values from these lanes. The LDLB is taken as Rf=1.0. Using the 
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transform function on all the x points, the function is X/K where K is the value identified 
to mark Rf=1.0.  
 
 
 
 
FUTURE DEVELOPMENTS 
 
 
The LpB system is useful for studying LP phenotypes in the common hyperlipidaemias 
and also in normal to moderately disturbed metabolism. It is a simple way of confirming 
dense species of LDL and for looking for unusually large species of HDL. It should be 
possible to reproduce it on larger gel systems but electrophoresis time may become 
impracticably long and may generate a lot of heat. The system should lend itself to 
transfer to membranes and immunodecoration to demonstrate qualitative differences in 
lipoproteins. In larger gels it may be possible to elute adequate amounts of material for 
sensitive methods to determine lipid (e.g. fluorimetric) and protein (e.g. immunoassays) 
contents. A combination of the two gels could be attempted as published from WV 
Brown’s unit.11  
 
The separation of HDL into preβ and α forms can be done in 2 dimensional 
electrophoresis in which the first dimension is in 0.1% agarose gels and the second 
dimension is in 2-30% non-denaturing acylamide gels.12   
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Appendix A.2 
 
 
 
TOTAL AND FREE CHOLESTEROL DETERMINATIONS WITH THE WAKO 
KITS 
 
 
GENERAL REMARKS 
 
 
Enzymatic assays for cholesterol are convenient and are commercially available until no 
longer viable or companies change policies. The lipid laboratory previously purchases the 
Boehringer Mannheim kit which was taken over by Roche and then discontinued. The 
advice from the Department of Pathological Biochemistry at the University of Glasgow 
was to purchase the kits now available from Wako, through orders placed in Germany. 
Wako Chemicals GmbH, Nissanstr 2, D-41468, Neuss, Deutschland (tel 02131311-0, 
facsimile 02131311100).  
 
The kit was adapted for small-scale use in the lipid laboratory so that it may be used for 
assays starting with dry lipid or wet samples. This required extensive optimisation with 
Mrs M J Levey. The total cholesterol (TC) and free cholesterol (FC) assays made by 
Wako use different colour products. The red quinone of the free cholesterol assay absorbs 
best at 505nm, while the blue pigment of the total cholesterol assay absorbs maximally at 
590nm. Bilirubin gives an enhanced absorbance, as does haemoglobin, in the free 
cholesterol assay.  
 
The methods were designed to resuspend dried cholesterol into ethanol (or isopropanol) 
with a small aliquot of Triton X100, whereafter reagents are added. Attempts were made 
to commit the standards and sample preparation to about 125ul and then to proceed with 
the assay so that about 250ul are available for the microtitre plate reader.  
 
 
FREE CHOLESTEROL ASSAY (274-47109E) 
 
 
CHEMISTRY 
 
 
Free cholesterol is converted to cholest-4-ene-3-one by reacting with oxygen in the 
presence of cholesterol oxidase and this step produces hydrogen peroxide on a molar 
ratio with cholesterol.  Next, 4-amino-antipyrene reacts with phenol and uses hydrogen 
peroxide in such a way that a red quinone pigment is formed along with water and a 
phenol that now has =O and =N at para-positions relative to each other. The colour is 
stable for 90 minutes.  
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MATERIALS 
 
 
Ethanol, absolute. 
Triton X100 1% v/v in distilled water. 
Saline. 
 
Reagent kit containing buffer, colour reagent, standard solution, and diluent for the 
standard. solution. Store in refrigerator although the standard solution and diluent. 
Buffer solution of 160ml contains 1% phenol and 0.1 molar phosphate at pH=7.0. 
Colour reagent of 75ml contains cholesterol oxidase 0.04U/ml, peroxidase 0.8U/ml, 4-
aminoantipyrine 0.015%. The colour reagent should be opened carefully as it is under 
negative pressure. It is stable at 2-4°C for two weeks after opening. Each bottle of colour 
reagent receives 75ml of buffer; prepared in either of two ways (1) first mix 10ml of the 
buffer with the powder by gentle inversion, transfer to a second container. Repeat this 2 
or 3 times before making up to 75ml with more buffer and mixing or (2) grind the 
material to a fine powder with a clean dry glass rod and add to 75ml of buffer. 
Standard solution (10ml) of cholesterol is at 100mg/dL and contains isopropanol, and 
the diluent (10ml) also contains isopropanol.  
 
 
ORIGINAL PROCEDURE 
 
 
This was designed for 50μl of sample and 3.0ml of reagent, with 50μl of standard being 
used for a concentration of 100mg/dL and 50μl of distilled water for a blank. The 
reaction is mixed and incubated at 37°C for 15 minutes. The absorbance is read at 
505nm. The reaction is linear up to 400mg/dL but higher concentrations require a 
dilution, in distilled water is recommended but saline will also be fine. 
 
The whole procedure can be scaled down to 10μl of standard or sample, and 300μl of 
reagent for microtitre plates. 
 
 
PROCEDURE FOR DRIED LIPIDS  
 
 
This procedure is designed for the use of dried standards and/or lipids but can incorporate 
aqueous samples. The dried lipid is dissolved in ethanol and triton and then admixed with 
saline whereas the aqueous samples are diluted with saline and then receive the triton and 
ethanol. The standards are aliquoted into microreaction vials and dried.  The range is 0-
100ug of cholesterol.  
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Use microreaction vials or 10x75mm glass tubes. Add 25ul of ethanol to the dried 
sample, vortex. Add 7.5ul 1% Triton and vortex. Add 92.5ul saline to bring the volume to 
125ul. To aqueaous samples, add saline to make the volume 92.5ul and then add 7.5μl of 
1% Triton and 25μl of ethanol.  
 
Add 125μl of reagent and mix. Transfer to a microtitre plate and react for 60 minutes at 
37°C. Read the absorbance at 500nm.  Using the mass of the standards on the x-axis, the 
optical density of the standards on the y-axis, derive the unknowns by interpolation, 
linear regression or non-linear regression.   
 
 
PROCEDURE FOR LIPIDS IN AQUEOUS SUSPENSION 
 
 
This assay requires a plasma standard with a previously determined free cholesterol 
concentration. The standard curve ranges from 0 to 100μg in 5 to 7 steps.  
 
The assay can be performed directly in a microtitre plate. The sample and balancing 
amount of saline should amount to 125μl. Add 125μl of reagent in such a way that the jet 
mixes the two components of the reaction. Tap the microtitre plate briefly to mix the 
reagent or shake in the microtitre plate reader. 
 
Incubate at 60°C for 1 hour. Read the absorbance at 500nm. Using the mass of the 
standards on the x-axis, the optical density of the standards on the y-axis, derive the 
unknowns by interpolation, linear regression or non-linear regression.   
 
     
TOTAL CHOLESTEROL ASSAY (L-type) 
 
 
CHEMISTRY 
 
 
Cholesterol ester is hydrolysed by cholesterol esterase in the presence of water, to form 
cholesterol and a free fatty acid. The cholesterol is reacted with oxygen by cholesterol 
oxidase, to form cholest-4-en-3-one and hydrogen peroxide.  Two molecules of hydrogen 
peroxide reacts with 4-aminoantipyrine and N-ethyl-N-(2-hydroxy-3-sulphopropyl)-3,5-
dimethoxyaniline Na (DAOS) in the presence of peroxidase to form a blue compound 
that absorbs maximally at 600nm.  
 
Plasma samples are stable for 1 week at 4°C to 12°C, and for 6 months at -20°C.  There is 
no interference from ascorbic acid (<50mg/dL), bilirubin (<684μmol/l), and haemoglobin 
(<500mg/dL). Lipaemic plasma is best diluted 4-fold before measuring.  The reaction is 
said to be linear up to 1000mg/dL. 
.  
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MATERIALS 
 
Isopropanol, absolute. 
Triton X100 1% v/v in distilled water. 
Saline. 
 
The reagent kit contains 4 bottles of colour reagent A, 4 bottles of colour reagent B, 
cholesterol standard 4 bottles of 10ml each.  
Reagent A: Good’s buffer (pH=7.0) at 0.1mmol/L, DAOS, cholesterol esterase 1U/ml 
and ascorbic acid oxidase 1U/ml. 413-10085:  4x70ml, 41410095: 4x270ml, 410-10095: 
4x540ml 
Reagent B: Good’s buffer (pH=6.5) at 50mmol/L, cholesterol oxidase 1.2U/ml, 
peroxidase 6U/ml, 4-aminoantipyrine 3.6mmol/L. 419-10185 4x24ml, 414-10195: 
4x90ml, 410-10195 4x180ml. 
Cholesterol Standard: 200mg/dL. 272-85009: 4x10ml.  
 
 
ORIGINAL PROCEDURE 
 
 
Sample or standard of 3μl is mixed with 270μl of reagent A and incubated at 37°C for 5 
minutes. Then add 90μl of colour reagent B.  Mix and react for 5 more minutes at 37°C, 
reading standards and samples at 600nm.  
 
 
PROCEDURE FOR DRIED LIPIDS 
 
 
To dried standards of cholesterol, 0-100μg in 5 to 7 steps, add 37.5μl of isopropanol and 
mix. Add 7.5μl of Triton X and mix. Add 80μl of saline and mix. Now add 120μl of 
reagent A and mix. Incubate at 37°C for 5 minutes and add 40μl of reagent B and mix. 
Incubate for 30 minutes at 37°C. Spin in high-speed centrifuge at 4°C to pellet insoluble 
material.  
 
Transfer 230μl to a microtitre plate well and read absorbance at 600nm.  
 
Use linear regression to obtain the μg of the unknown from the standard curve. The r2 = 
0.998. 
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PROCEDURE FOR AQUEOUS SUSPENSIONS OF LIPIDS 
 
 
The standard is a well-characterised serum/plasma sample that is placed in a standard 
curve representing 0-100μg in 5 to 7 steps.  
 
In a microtitre plate well, bring the standards and samples to 125μl with saline. Mix by 
gently tapping the microtitre plate on the side or by placing on the shaker of the 
microtitre plate reader.  Add 120μl of reagent A, incubate for 5 minutes at 37°C. Add 
40μl of reagent B and incubate for 30 minutes at 37°C. Read the absorbance  
 
Use linear regression to obtain the μg of the unknown from the standard curve. The r2 = 
0.9998. 
 
 
REFERENCES 
 
 
1. Wako package inserts 
2. Laboratory records 
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Appendix A.3 
 
 
 
GPO PAP KIT FOR TG ASSAY 
 
 
GENERAL 
 
 
Lipases hydrolyse triacylglycerol to free fatty acids and glycerol, which is converted to 
glycero-3-phosphate by glycerokinase and ATP. The glycerophosphate is reacted with 
oxygen by glycerophosphate oxidase yielding dihydroxy- acetone-P and H2O2. Two 
molecules of the latter is used by peroxidase as well as 4-aminoantipyrine and 4-Cl-
phenol to generate quinoneimine HCl and 4H2O, yielding a pink-red colour read at 
500nm (or 546 in Hg) in a 1cm path. Kit no:10164. 
 
 
MATERIALS 
 
 
BUFFER solution contains Pipes (pH=7,5) 40mmol/l, Mg 5mmol/l and chlorophenol 
5mmol/l and NaN3 0,1g%. 
ENZYMES solution contains aminoantipyrine 0,4mmol/l, ATP 1 mmol/l, lipases 
>150U/ml, glycerokinase >0,4U/ml, glycero-3-P oxidase > 1,5U/ml, peroxidase 
>0,5U/ml. Reconstitute the enzyme lyophilisate with 15ml buffer. This will be stable at 
4°C for 21 days or 20°C for 3 days. 
 
CALIBRATION. Commercial calibration sera can be employed but it is cheaper to use 
gravimetric standards although now ethanol must be employed to dissolve the 
triacylglycerol. Use sunflower oil or triolein. Dissolve 10,0mg in 10ml benzene and mix 
for 1ug/ul (soln A) and take 200μl for bringing to 2ml for 0,1μg/μl (solution B). Prepare 
2,5; 5 and 10μg standards from B and 25, 50, 75, 100, 125, 150, 175 and 200μg standards 
from A. Dry in fume cupboard. 
 
 
PROCEDURE FOR MICRO-REACTION VIALS 
 
 
This design is for a final volume of about 750μl and allows reading in a microcuvette in a 
spectrophotometer and also a transfer of some of the reacted solution to a microtitre plate 
for rapid reading. 
 
PLASMA. A standard is provided with the kit. Blank has no plasma while 10ul of sample 
is reacted, or in turbid plasma a dilution. Add 250μl of saline, vortex. Add 500μl of 
reagent, vortex. Incubate at room temperature for 15 minutes and read within an hour. 
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EXTRACTS. Dry the lipid extract transferred in organic solvent (glass or other insoluble 
tube). Prepare blank and standards (2 to 200μg, similarly dried). Add 20μl ethanol, 
vortex. Add 250μl saline, vortex. Add 500μl reagent, vortex. Incubate 15 minutes and 
read absorption. 
 
Analyse by linear regression, r=0,999. Ethanol affects neither blank nor standard readings 
and two assays can be combined, adding saline first to plasma samples to avoid ethanolic 
denaturation. Subtract 0,11mmol/l for free glycerol. 
 
 
PROCEDURE FOR MICROTITRE PLATE 
 
 
Performing this assay in a microtitre plate makes the assays rapid and cheap. It is 
designed for a standard or sample volume of 50μl and 200μl of reagent. However, the 
sample volume can be made smaller if only plasma is being analysed. 
 
Using the calibrator with the kit (2μg/μl) a standard curve is set up from 0.5μg to 60μg so 
that there is a blank and 5 points for linear regression. Plasma samples should be between 
2 and 10μl, depending on the triglyceride content. Very lipaemic samples have to be 
diluted in saline before use in the assay. Once the volumes have all been brought to 50μl, 
add 200μl of reagent. Stand for 15 minutes. Shake for 30 seconds before reading in the 
machine at 500nm. 
 
Analyse by linear or non-linear regression. 
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Appendix A.4 
 
 
 
SIGMA 3-α-hydroxy BILE ACID ASSAY 
 
 
GENERAL 
 
 
BILE ACID METABOLISM 
 
 
Bile acids are synthesised in the liver and concentrated in bile. They can be found in the 
blood only at low concentrations owing to a very efficient enterohepatic circulation. 
Their synthesis characteristically includes the switching of the position of the 3-OH 
group from beta to alpha orientation on the sterol, as well as the addition of other -OH 
moieties and the cleavage of the isooctyl side chain of the sterol. Thereafter follows 
conjugation to glycine and taurine. 
 
 
QUANTIFICATION 
 
 
Bile acids can be quantified by gas chromatography, fluorimetric or spectrophotometric 
methods, or by immunoassay. This method is an enzymatic assay in which, in the 
presence of NAD, 3α hydroxysterol dehydrogenase from fungi is used to create 3 oxo-
hydroxysterol and NADH. Next NADH and nitroblue tetrazolium (NBT) salt produce 
NAD and formazan. Formazan has a maximal absorption at 530nm (still suitable at 
540nm), and the intensity of the colour is directly proportional to the amount of bile acid. 
Adding phosphoric acid can stop the colour generation. The assay is strictly speaking for 
3α-OH sterols and will thus reflect bile acid concentration as well as cholestanol 
concentration. 
 
The assay takes into account the other plasma dehydrogenases of which the most 
important is lactate dehydrogenase (LDH). Heating plasma to 67°C for 30 minutes will 
inactivate all enzymes but is tedious. Since the bulk of the plasma or serum 
dehydrogenase activity resides in LDH, it is possible to block this activity with sodium 
pyruvate (200mmol/L), or oxamic acid. The stop reagent is phosphoric acid at 
1.33mmol/L with 200mmol/L sodium pyruvate. The optimal NBT concentration is 
0.2g/L. In order that formazan precipitation is avoided, a non-ionic detergent, 
polyoxyethylenolylether is added. 
 
The enzymes used in the assay are sensitive to the bile salts in pure solutions that may be 
used as standards, especially when the enzymes are ageing. The result is an 
underestimation of the colour change leading to an exaggeration of the concentration is 
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the samples. This can be avoided by adding protein to the standards’s solution, typically 
to a final concentration of 2g% in the standard.  
 
The samples should be taken in plain tubes after an overnight fast and clot should be 
removed. Serum can be kept at 4°C for a day or frozen until the assay, at -20°C. The 
normal fasting range for bile acids is 0-8μmol/L.  The assay is linear up to 200μmol//L. 
The intra-assay coefficient of variation (CV) is about 1-7% and the inter-assay CV is 
about 2-8%. An increase in the systemic concentration of bile acids means either 
significant porto-systemic shunting or poor hepatic extraction during enterohepatic 
circulation.  A decrease indicates bile acid malabsorption. 
 
The lipid laboratory has modified the assay to a microtitre plate. A solution of sodium 
deoxycholate is used as standard.  Subjects with liver disease or who are expected to have 
a high concentration should have their samples diluted with saline, either 1 in 5 or 1 in 
10. 
 
The reference 95% confidence interval in a group of healthy adults was found to be 14-
20μmol/L (n=14). The mean and standard deviation were 16.6 and 4.2 μmol/L 
respectively and the range was 8.5 to 25.  This needs reconfirmation after discovering the 
matrix effects. 
 
Sigma discontinued manufacture 2003 and a similar kit has been devised by Adcock 
Ingram for approx R6000 in 2004 for 40 samples.  Samples should be provided as serum 
but the addition of calcium to at least 10mmol/L final concentration may enable analysis.  
 
 
MATERIALS 
 
 
SAMPLES. Fasted serum. No anticoagulants. It is possible to use EDTA plasma which 
has been enriched with Ca chloride to a final concentration of 20mmol/L.  
 
BILE ACID REAGENT A. Cat No 450-1. Store at 4°C. Contains NAD at 2.5mmol/L, 
NBT 0.61mmol/L, diaphorase 625 U/L, buffered to pH=7.0. Reconstitute with distilled 
water. Invert but do not shake or vortex. Stable for at 4°C for 1 week, at room 
temperature for 24 hours. 
 
BILE ACID REAGENT B. Cat No 450-2. Store at 4ºC. 3α Hydroxysterol dehydrogenase 
1250 U/L with stabilisers. Reconstitute with distilled water. Invert to mix but do not 
shake or vortex. Stable for at 4ºC for 1 week, at room temperature for 24 hours. 
 
The reagents should not be caked and should dissolve completely for proper reactions. 
The reconstituted solutions should have an optical density (OD) of <0.3 against distilled 
water.  
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BILE ACID STOP REAGENT. Cat No. 450-3.  Na-pyruvate (MW 110.05) at 
200mmol/L in phosphoric acid 1.33mmol/L. 
BILE ACID CALIBRATOR. Cat No. 450-100. 
BILE ACID CONTROL SERUM. Cat No. 450-22. 
 
ALBUMIN 4g% SOLUTION for dilution. 
BILE ACID HOME STANDARD. Na Cholate has molecular mass of 430.6d. Note that 
the Sigma preparation is mixed conjugated bile salts and does not give molarity expected.   
 
 
PROCEDURE 
 
 
Prepare the reagent solutions A and B, and samples and warm them to 37°C. The active 
test reagent is A+B (4 volumes A + 1 volume B) while the blank reagent is 4 volumes 
of A plus water 1 volume. 
 
In the original procedure the sample volume is 200μl, the reagent volume is 500μl and 
the stop solution volume is 100μl. The calibrator is used and the assay is assumed to be 
linear. The reaction time is said to be 5 minutes but the Lipid laboratory experiences 
better linearity, especially at larger amounts of standard, if the reaction runs for 45 
minutes. 
 
 
MICROCUVETTES  
 
 
Set up tubes to reflect a range of standards and their blanks, a Calibrator, a Calibrator 
blank, a Control and a Control blank, a Sample and Sample blank. Prepare the standards 
in 100μl such that saline makes up 50μl and with 50μl being 4% albumin solution to 
avoid matrix effects. Pipette in 100μl of calibrator, control and sample into the relevant 
tubes. Pipette in 250μl of test reagent to all the active assays and blank reagent to all the 
blank assays. Take note of the timing, as the reaction times have to be identical. 
  
Let the reaction proceed for 45 minutes and then add stop reagent, 50μl at the exact 
intervals for all tubes. The colour is stable for 1 hour.  
 
Read the OD at 530nm and calculate the change between active and inactive assays. 
Derive the concentration of unknowns by regression curve analysis from the known 
values.  
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MICROTITRE PLATES 
 
 
The same as above. The standard curve is made up from 1 to 50nmol of 3α hydroxysterol 
as cholic acid. The standards and samples are presented in 100μl, which should be 
balanced with 4g% albumin to avoid matrix effects when <100μL is used. Serum 
expected to have normal values should be 100μL.  Add 250μl of reagent or reagent blank. 
Add 50μl of stop solution.  
 
 
CALCULATIONS 
 
 
The bile acid content in the assay is calculated by linear or non-linear regression, or by 
proportion to a known concentration. Noting that changes in absorbances for test and 
blank reagents are used to derive the Δabsorbance for the unknown (U) and calibrator    
(C), the serum bile acid concentration can be calculated from the umol/L of C. 
 
uM/L unknown = (ΔU/ΔC)*([C]) 
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Appendix A.5 
 
 
 
CHEMICAL PRECIPITATON OF LIPOPROTEINS 
 
 
GENERAL 
 
 
Polyanions (heparin, dextran) and cations (Mg, Ca, Mn) have a specificity of 
precipitating lipoproteins according to their concentration, the lipid/protein ratio of the 
lipoprotein, and environmental factors in the reaction (protein, solute & chelatant 
concentrations and pH). Precipitation is complete within 10 minutes and is stable for 
hours. The first to last in sequence are CM, VLDL, LDL, and HDL. It is probable that 
apo-E in HDL does not coprecipitate under conditions bringing apoB down when using 
heparin-Mn but will coprecipitate with dextran-Mg and phosphotungstate-Mg.  
Hypertriglyceridaemia (>3mmol/l) may interfere with complete precipitation and the 
VLDL may be first spun up or subsequently the sample should be spun harder to 
sediment the apoB containing lipoproteins. On ageing (>4days) apoB tends to precipitate 
less completely if low HDL, while more if high HDL. These effects are lessened by 
storing at -20°C or -70°C. Mn can interfere with subsequent enzymatic assays and should 
be removed by bicarbonate rather than EDTA since the latter also interferes. 
 
Polyethylene glycol can also effect LP precipitation by altering the dielectric constant of 
the water, and its concentration (60-120g/l final) and pH affect the extent of precipitation 
and triglyceride has very little effect up to 15mmol/l. All the above methods agree very 
well with ultracentrifugation. The use of enzymic reagents for heparin-Mn has the added 
complication of incomplete LpB precipitation with EDTA, Mn-EDTA turbidity and 
phosphate-Mn turbidity unless bichromatic correction and reagent addition of EDTA to 
chelate Mn is made. 
 
Turbid samples can be clarified by (i) dilution with saline before the procedure, (ii) 
dilution with saline after the procedure so that the density is lower for improved 
precipitation, (iii) ultrafiltration through Millipore 0,22um pore size but larger volumes 
are required and losses of HDL may occur. In general the least interference can be 
expected from polyethylene glycol (PEG) method which does not interfere with enzymic 
reagents, yields very good precipitations even on old specimens but can read 0,05mmol/l 
lower with EDTA. It also tolerates high triglycerides best. 
 
 
MATERIALS 
 
 
HEPARIN Na. Porcine intestinal mucosal (35mg= 5000 USPU). Keeps for months in 
fridge. 
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MnCl2+4H2O. 197,7g/M. Final conc 0,042 to 0,092mol/l. Keeps for months as 
concentrated stock solution. 
DEXTRAN SO4 (50kd) Stock solution usually 2% at pH=7,0.  
MgCl2+6H2O at 1mol/l, pH=7,0. 
 
 
PROCEDURE 
 
 
Usually 100μl of 10X stock of mixed heparin/Mn (or dextran/Mn or dextran/Mg) is 
added to 1,0ml of plasma and the apo-B containing lipoproteins are precipitated for 15 
minutes before being spun at 6000G for 10 minutes. The cholesterol concentration in the 
supernatant is determined and corrected by a 10% increase to allow for the dilution by the 
additives, yielding the "HDL-C". 
 
HEPARIN-Mn. Final concentration for plasma is heparin 0,2% and Mn 0,092mol/l. 
Plasma diluted x10 with saline requires only 0,005%. Add 10X Mn-heparin stock to 
appropriate volume at room temperature, standing on ice (not essential) for 15 minutes 
before pelleting the lipoproteins by 6000G for 10 minutes. Note the white pellicle is Mn 
oxide and not floated lipoproteins. The supernatent "HDL" is removed by aspiration. 
 
Heparin is removed by precipitation with 5% BaCl2 whereas Mn is removed by 
precipitation with 10% NaHCO3. Spin for 3 minutes to remove cleared supernatent. 
Lipoproteins are redissolved by 1 to 5% NaCl (incubate 30 minutes at 37°C) or 10% 
NaHCO3, or by adjusting pH to <4,0 or >8,8.  
 
HEPARIN MgCl2. Final concentration is 0,05% heparin and 0,1mol/l Mg. This 
concentration will precipitate all lipoproteins. Prior solution of 1g/ml sucrose in plasma 
will cause precipitation of only apoB-containing lipoproteins which will float on 
centrifugation so that HDL is retrieved by piercing the tube and aspirating the infranatant. 
More heparin is required as sucrose is decreased. 
 
DEXTRAN MgCl2 tends to precipitate more apoAi but more complete apoB 
precipitation. Final concentration is 0,91mg/ml and Mg 0,045mol/l. 
 
DEXTRAN MnCl2. Final concentration is 0,05% with Mn 0,05mol/l. 
 
PEG Fluka/Sigma Mr=6000.  Dissolve 45g in 60ml distilled water, bring to 100ml. 
Stores at room temperature for 2 months. To 1ml of serum add 200ul of solution and 
vortex. Keep at room temperature for 15 minutes. Spin in microfuge for 15 minutes at 
2300G. Determine the cholesterol concentration in the supernatant and correct for 
dilution by 1,2. 
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HDL SUBFRACTIONATION (GIDEZ) 
 
 
Variations in total HDL concentrations are primarily due to HDL2 concentration 
variations. HDL2 and HDL3 levels were previously measured following 
ultracentrifugation. This method cannot be applied to large numbers of samples, therefore 
use precipitation methods to separate HDL2 and HDL3.The method devised by Gidez et 
al. is a dual precipitation method, in which apoB-containing lipoproteins are first 
precipitated. HDL2 is then precipitated from the clear HDL containing supernatant. 
Cholesterol is then analysed in the first (total HDL) and second (HDL3) supernatants and 
HDL2 cholesterol is calculated as the difference between the two. 
 
 
MATERIALS 
 
 
MnCl2+4H2O 1,12mol/l (22,166g% in distilled water). 
Heparin 135mg/ml (2,025g Na heparin in 15ml, or 20000USP U/ml).  Commercial 
source 168mg/ml. 
Dextran (15000) 14,3 mg/ml. 
MIX 6ml of heparin and 50ml of Mn for 14,5mg/ml heparin and 1mol/l MnCl2 which in 
reaction will become 1,3mg/ml and 0,091mol/l. 
 
 
MICROSCALED PROCEDURE FOR LIPID LABORATORY 
 
 
Transfer 600μl plasma to a 1.5ml Eppendorff tube. Add 60μl MIX and mix thoroughly 
but avoid foaming. Allow the sample to stand at room temperature for 20 minutes, then 
centrifuge at 1500g for 1hour at 4°C.Immediately remove an aliquot of clear heparin-
MnCl2 supernatant for the analysis of total HDL-cholesterol and another for HDL2 
precipitation. 
 
HDL2 precipitation: Transfer 300μl clear heparin-MnCl2 supernatant to an Eppendorff 
tube. Add 30μl dextran sulphate solution to the sample and mix well. Let the sample 
stand at room temperature for 20 minutes, then centrifuge at 1500g for 30 minutes at 4°C. 
The clear soluble fraction represents HDL3. 
  
The measured value for total HDL-cholesterol is multiplied by 1.10, and that for HDL3 is 
multiplied by 1.21 to correct for dilution by the reagents. HDL2 is then calculated as the 
difference between total HDL-cholesterol and HDL3-cholesterol. 
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LARGE SCALE PROCEDURE 
 
 
Lower density lipoproteins are first precipitated by adding 300μl of the MIX to 3,0ml 
plasma, vortexing, and standing at room temperature for 20 minutes. Spin 1 hour at 
1500G at 4°C. Supernatant contains whole HDL. 
 
Partial HDL precipitation is done by adding 200μl dextran solution to 2,0ml of above 
supernatant, vortexing and standing for 20 minutes at room temperature. Spin 30 minutes 
at 4°C. Measure the HDL3 concentration in the supernatant. 
 
Calculate the whole HDL by multiplying the first supernatant concentration by 1,10 and 
the HDL3 by multiplying the concentration in the second supernatant by 1,21. The HDL2 
concentration is the difference. 
 
 
 
OTHER METHODS 
 
 
Wilson has described a method whereby VLDL-C, LDL-C and HDL-C can be derived by 
various precipitation techniques without involving the Friedewald equation, but on a 
fasted sample.1 VLDL is aggregated by SDS between 0.6 and 0.75% but not at 
concentrations higher than 1.5%. Under these conditions some SDS already associates 
with LDL and HDL as they now migrate faster on electrophoresis.  This step allows the 
estimation of LDL-C and HDL-C. HDL-C alone is estimated by Ca-dextran sulphate or 
heparin-Mn precipitation of LpB (latter method is more quantitative). Wilson described 
the method with EDTA plasma and found it suitable at least in some 
hypertriglyceridaemias, provided that the infranate of the VLDL aggregate is clear. 
 
Firstly, total plasma cholesterol is determined, as well as triglyceride. One limb of 
procedures involves the VLDL aggregation. To 2 ml of plasma add 0.1ml 22.2% CaCl 
and 0.08ml Na dextran sulphate (MW 2E6, Sigma), incubate for 24 hours at 4°C. 
Centrifuge at 4°C for 20 minutes at 2500 rpm (no G force given). Determine the HDL-C 
in the supernate. The other limb is the aggregation of VLDL.  To 2 ml of plasma add 
0.15ml of 10% SDS in saline pH=9.0. Incubate for 2 hours at 35°C. Spin at 10 000G at 
ambient temperature for 10 minutes. The pellicel is VLDL. Aspirate the infranate to 
determine HDL-C and LDL-C.  
 
The different fractions are now calculated: TC - (HDL-C + LDL-C) = VLDL-C, 
(HDL-C+LDL-C)-HDL-C = LDL-C.  
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Appendix A.6 
 
 
 
AGAROSE GEL LIPOPROTEIN (LP) ELECTROPHORESIS 
 
 
GENERAL 
 
 
An inexpensive, simple procedure by which a few μl of plasma can be analysed for its 
lipid content in lipoproteins, and diagnostic of type III dyslipoproteinaemia. Usually 
performed in an alkaline buffer made up of barbituric acid, and agarose gels while 
cellulose acetate or paper electrophoresis are also feasible. The chylomicrons remain at 
the (cathodic) origin while the other LP are separated from cathode to anode as beta- 
(LDL), pre-beta- (VLDL) and alpha-LP (HDL) with the fats in albumin often giving a 
faint stain nearest the anode. Densitometric scanning aids the interpretation by giving 
areas under relevant parts of the curve. Knowledge of the plasma lipids is useful in the 
interpretation as well. 
 
A 10-14 hours fasting plasma (EDTA) or serum sample should be analysed immediately 
or could be stored at 4°C for up to 72 hours. Do not use heparinised samples. 
 
 
MATERIALS 
 
 
Most convenient is the LIPO kit with the Beckman Paragon system. This has sealed, pre-
prepacked gels which must be kept horizontal in storage. The buffer contains, when 
reconstitiuted, 50mmol/l 5-diethylbarbituric acid, while the gel is made in this containing 
also 0,1% Na azide in 0,5% agarose. Never freeze the gels; store at room temperature. 
Use absolute ethyl alcohol for making up solutions. 
 
BUFFER is made up by dissolving the bottle's contents in 1,5L distilled water and 
pH=8,6. Stores at room temperature for 60 days. 
FIXATIVE SOLUTION is 180ml alcohol with 90ml distilled water and 30ml glacial 
acetic acid. 
STAIN comes prepacked as 7% Sudan Black B, made up to to 0,07%. To 165ml of 
alcohol add 3ml of stain kit and add 135ml distilled water before stirring for 10 minutes. 
Stable at room temperature for 7days. 
DESTAIN SOLUTION is 450ml of alcohol with 550ml distilled water. Set up 3 flasks of 
300ml each. 
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PROCEDURE 
 
 
An application template is used to apply 3-5μl of serum or plasma for 5 minutes. A 
blotting strip is now used to remove excess plasma. 
 
The gel is placed in the correct orientation in the dish containing 45ml of buffer. The 
machine is switched on for the appropiate number of dishes and for 100V, for 30 to 40 
minutes. 
 
Upon completion remove the gel and place in frame. Place in fixative for 5 minutes, 
remove and wipe moisture off its back. Dry the gel at 50°C. Now place in working stain 
for 5 minutes. Dip in destain flask 1 three times, then in flask 2 thrice and in flask 3 for 5 
minutes. Wipe off excess liquid and dry. 
 
 
INTERPRETATION 
 
 
The pattern may be interpreted visually or be analysed by densitometer at 600nm. In 
either case a normal control serum of known LP constitution is useful and may even be 
used as a standard in the scanning which should also yield areas under the curve as a 
fraction of total area. The CV is <5% according to the package insert. 
 
Another method of quantifying the electrophoretogram is to elute Sudan Black with 
acetic acid/ethanol/water 11:5:4 and to read the absorbance. The lipid in a given fraction 
is then expressed by LF=TXDF/DT where T is absorbance and DF and DT are the dye in 
the fraction and total dye. The staining is however not equal for all lipids; if CE=1, 
TG=0,8 and PL 0,1 and FA 0,1 and free cholesterol is 0,02. Because of the differential 
lipid staining the corrected fraction that should be used for DF is 1 for alpha, 0,75 for beta 
and 0,75 for prebeta and 0,63 for CM. For Fat Red 7B the corresponding corrections are 
1,75; 1.0 and 0,82 and 0,82.1 
 
A NORMAL pattern has <1% of lipid stain in CM, 40-70% in beta, 0-30% in pre-beta 
and 10-45% in the alpha band. 
 
 
FREDRICKSEN CLASSIFICATION 
 
 
TYPE I shows a definite dark band at the origin and frequently a smearing across the 
other bands to the alpha band. TYPE II has a more intense than normal beta. IIa has only 
this change while IIb has more than normal intensity of pre-beta as well and will have TG 
values slightly to definitely elevated. In TYPE III there is an abnormally broad band 
starting anodic to the usual beta site and ending at towards the anodic end of the pre-beta 
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band; sometimes some CM may be seen as well and alpha band may be feint. TYPE IV 
has increased pre-beta staining and often also diminished beta and alpha intensity. TYPE 
V has CM stain at origin, often smears as well, and in addition also has intenser staining 
of pre-beta while alpha staining often reduced. 
 
In abetalipoproteinaemia there is no visible beta or pre-beta band. In 
hypoalphalipoproteinaemia the band is poorly staining while in 
hyperalphalipoproteinaemia it stains intensely. 
 
 
UNUSUAL FINDINGS 
 
 
A sinking pre-beta band due to larger quantities of Lp(a) can be seen at the cathodic end 
of the pre-beta band. The Lp(a) cholesterol can be calculated by the use of absorbance of 
Lp(a) (Aa) and beta band (Ab) and the total cholesterol (T): Lp(a) C = TX(Aa/Aa+Ab).  
Another diagnostic clue can be a very rapidly migrating beta band (LDL) in X-linked 
ichthyosis where steroid sulfatase is deficient and this results in the accumulation of 
cholesterol sulfate and thus more (negatively) charged LDL.   
 
Heparinised samples present charged lipoproteins which migrate aberrantly in a fast, or 
streaking fashion. Aged samples may undergo lipolysis and the negatively charged fatty 
acids will permit fast migration of the beta band, and at 3umol/L will create a pre-beta 
migrating beta band and may aslo stain up on albumin. This phenomenon of accelerated 
beta migration can be cancelled by adding fat-free albumin to adsorb the fatty acids.  
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Appendix A.7 
 
 
 
PHOSPHOLIPID BY CHOLINE ASSAY KIT 
 
 
GENERAL 
 
 
The indications for measuring phospholipids are less commonly encountered than for 
measuring plasma cholesterol and triglyceride but phospholipids have a special role in the 
detection and following of dyslipidaemia in obstructive jaundice because LpX is so rich 
in phospholipid. Furthermore, maternal amniotic fluid is examined for fetal lung 
maturity, reflected in phospholipid concentration.  
 
The assay methods for phospholipid classically were to extract the lipid by a procedure 
such as that of Folch, to mineralise the sample to inorganic phosphorus and then to 
demonstrate phosphorus through a colour development.1 The oxidation to mineralise the 
sample is done with perchloric acid (± hydrogen peroxide) at 200°C to 225°C for 15 
minutes, or with a mixture of sulphuric and perchloric acid and vanadium pentoxide as 
catalyst.  
 
The assay meaures phosphatidylcholine (lecitihin), the bulk of phospholipids in blood 
and cell membranes. 
 
This enzymatic method involves the hydrolysis of phospholipids by phospholipase D, 
releasing choline and phosphatidic acid. The choline, in the presence of 2 oxygen 
molecules and water, by means of choline oxidase, forms betaine and 2 molecules of 
hydrogen peroxide. Two hydrogen peroxide molecules react with 4-aminophenazone and 
phenol to yield 4(p-benzoquinone-mono-imino)phenazone and 4 water molecules. The 
enzyme is a peroxidase. The absorbance is measured at 500 to 505nm. 
 
The assay is for moles of phosphatidylcholine, and not necessarily all phospholipid. The 
average molecular mass of phospholipid is 774d. The reference range is 158-284 mg/dL 
or 2.04-3.66 mmol/L. The assay behaves linearly and only one reference point is 
required. Serum or plasma (citrate, heparin) can be used, but not plasma containing 
EDTA for the Boehringer Mannheim kit. The Wako kit is compatible with serum, and 
plasma using EDTA, heparin, oxalate, and citrate. The samples are stable for 7 days at 
4°C, and 2 days at room temperature but can be frozen for years.  Ascorbic acid can 
interfere with colour production when present in high concentration, and haemoglobin 
and bilirubin can yield increase in absorbance when unusually high in concentration.  
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BOEHRINGER MANNHEIM KIT 
 
 
Boehringer Mannheim kit: 691844. 5x40ml vials. Discontinued in 2001. Once prepared, 
the reagents from the kit are stable for 2 weeks at 4°C and 2 days at room temperature.  
Wako kit. 990-54009E. Caters for 50 test units: 190mL buffer, 4 vials colour reagent, 
standard is the same as for Boehringer Mannheim kit.  
 
Standards. Choline 54.1mg% equivalent to 300mg% PC. The formula for choline is 
C5H15O2N and mass is 121.2d. Hence each ul contains 0.541ug or 4.46nmol/l. 
Buffer. Set at pH=8.0. Tris-hydroxymethylaminomethane 50mmol/l, phenol 20mmol/l.  
Reagents. PLase D >10E4U/L, choline oxidase >800U/L, 4-aminophenazone 8mmol/l.  
 
 
PROCEDURE FOR MICROREACTION VIAL 
 
 
Set up a reagent blank with water in equivalent volume to plasma, a calibration standard, 
and the samples for analysis.  
 
ORIGINAL. Use 20μl of sample or calibrator, add 3ml reagent, mix. Incubate at room 
temperature for 20 minutes or at 37°C for 10 minutes. Read the optical density at 500nm. 
 
MODIFIED. Use the appropriate pipetteman or positive displacement pippete to aliquot 
7μl of sample or calibrator. Add 1ml of reagent. Mix, incubate as above, and determine 
optical density. 
 
CALCULATE. Derive the change in absorbance by subtracting the value of the reagent 
blank from that for the sample(s) or calibrator. The sample concentration is 
300x(dODsample/dODcalibr) in mg/dL. For mmol/L the calculation is 
3.88x(dODsample/dODcalibr). The reaction is linear up to 13mmol/l or 1000mg/dL. 
 
 
PROCEDURE FOR MICROTITRE PLATES 
 
 
Scaling the assay down for a microtitre plate makes it both cheap and rapid. The design is 
for 50μl up to 100μl of sample and 150μl up to 250μl of reagent. 
 
The standard curve is set up with the choline solution, having diluted the solution for the 
lower part of the curve. The standard curve should be from 0.0541μg to 5.415μg. The 
plasma (5-15μl) or other samples should also be brought to 100μl. Add 150μl of reagent. 
Stand for 30 minutes at room temperature, shake briefly before reading in the machine at 
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500nm. Alternatively, incubate at 37°C in an incubator for 10 minutes, stand at room 
temperature for 5 minutes and read absorbance. 
 
Analyse against the standards by linear or non-linear regression, depending on the curve 
and the optical density of the samples. 
 
 
WAKO PHOSPHOLIPIDS B KIT 
 
 
The chemical basis is the same as for Boehringer Mannheim kit that was discontinued in 
2001.   
 
Code No. 990-54009E. Store at 2-10°C (do not freeze) A 50-test unit comprises: 
Buffer 190ml.  Tris 0.05 Molar, pH=8.0, Ca chloride 5mg/dL, phenol 0.05%. 
Colour reagent in 4 vials each 45 when reconstituted. Per vial: Phospholipase D 20U, 
choline oxidase 90U, Peroxidase 240U, 4-amino-antipyrine 0.015% when reconstituted. 
 
Standard solution. 10mL corresponds to 300mg/dL (3g/L or 3.88mmol/L) of 
phospholipid and contains 54mg/dL (0.54g/L or 5.2mmol/L) of choline, and phenol 1%.     
 
 
ORIGINAL ASSAY 
 
 
20μL of sample or standard or distilled water for the blank, is mixed with 3.0mL of 
reagent. Place at 37°C for 10 minutes. Colour develops in 5 minutes but the reaction can 
proceed at this temperature for another 15 minutes. The colour is stable for 2 hours.  Read 
at 500 to 505nm.  
 
Beer’s Law is obeyed at 0-1000mg/dL of phosphatidylcholine. Thus, within the range of 
3 times the corrected absorbance for the standard sample, the unknown concentration can 
be derived: 
 
Unknown mg/dL = (Au /As) x (300mg/dL) 
Unknown mmol/L = (Au /As) x (3.88 mmol/L) 
 
 
PROCEDURE FOR DIRECT ASSAY IN MICROTITRE PLATES 
 
 
Scaling the assay down for a microtitre plate makes it both cheap and rapid. The design is 
for 50μl (up to 100μl of sample) and (150μl up to) 250μl of reagent. 
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The standard curve is set up with the choline solution (0.54μg/μL), having diluted the 
solution for the lower part of the curve. The standard curve should be from 0.0541μg to 
5.415μg choline, corresponding to 0.3 to 30μg phosphatidylcholine.  
 
The plasma (5-15μl) or other samples should also be brought to 100μl. Add 150μl of 
reagent. Stand for 30 minutes at room temperature; shake briefly before reading in the 
machine at 500nm. Alternatively, incubate at 37°C in an incubator for 10 minutes, stand 
at room temperature for 5 minutes and read absorbance. 
 
Analyse against the standards by linear or non-linear regression, depending on the curve 
and the optical density of the samples. 
 
 
PROCEDURE FOR ASSAY OF DRIED LIPIDS FOR MICROTITRE PLATES 
 
 
The dried lipid material is first resuspended. To the dried sample, add 50μL of ethanol, 
vortex. Add 15μL of 1% Triton X-100, vortex. Add 185μL of water, vortex.  The 
standard curve uses the same standard curve as for the microtitre plate. The standard 
curve and blank are prepared similarly with ethanol and Triton.  
 
Now add 250μL of reagent. Incubate at room temperature for 30 minutes or 37°C for 10 
minutes. Transfer 250 to 300μL to the microtitre plate.  Read absorbance at 500 to 
505nm. 
 
Using linear or nonlinear regression, the standard curve data allow the calculation of 
mass of unknown phospholipid.  
 
Note, to limit costs, 125μL of suspension can be transferred to a microtitre plate well and 
reacted with 125μL of reagent.    
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